

# Index

Page references followed by *f* denote figures; those followed by *t* denote tables.

## A

- Abazyme, LLC, 424  
Accuracy, ELISA, 641  
Acidic stripping buffer (recipe), 528  
Acids  
  disposal of, 821  
  safe handling of, 820, 823  
Activated carbon, coupling antigens to, 63  
Activation-induced deaminase (AID), 17  
Adaptive (acquired) immunity  
  clonal selection and, 4–6, 5f  
  described, 1–2  
  link to innate immunity, 2–3  
ADCC (antibody-dependent cellular cytotoxicity) by flow cytometry (protocol), 751–754, 752f–753f  
Adherent cells  
  growing  
    on coverslips or multiwell slides (protocol), 686  
    on tissue culture dishes (protocol), 687  
  preparing for staining, 679  
Adjuvants, 2, 33–34, 113–116  
  advantages and disadvantages of specific, 114t  
  aluminum hydroxide, 116, 148–149  
  Freund's, 114–115, 142–143, 143f  
  GERBU, 116  
  Hunter's TiterMax, 115, 145  
  Magic Mouse, 115, 146–147  
  overview of, 113–114  
  Pam3Cys-Ser-(Lys)4, 115–116  
  protocols, 136–149  
    aluminum hydroxide (alum) adjuvant preparation, 148–149  
    Freund's adjuvant preparation, 142–143, 143f  
    Hunter's TiterMax adjuvant use, 145  
    Magic Mouse adjuvant use, 146–147  
    Ribi adjuvant use, 144  
  Ribi, 115, 144  
  as TLR agonists, 2  
Adoptive transfer immunization of mice (protocol), 191  
Affinity of antibody–antigen interaction, 24–28, 25t, 26f–27f  
  bivalent binding  
    of antibodies to polymeric antigens, 25, 26f  
    to antigens immobilized on solid supports, 27f, 28  
  factors affecting strength of binding, 25t  
  intermolecular bridges and, 25, 26f  
  monoclonal antibody binding to multimeric antigen, 25  
  multivalent complexes, 25–28, 26f–27f  
    secondary reagents and, 27f, 28  
Affinity. *See also* Affinity purification  
  of antibody–antigen interaction, 24  
  of IgG versus IgM, 39  
  measurement of, 358–361  
    ELISA, 358–359  
    equilibrium dialysis, 358  
    labeling experiments, 359–360  
    optical biosensor methods, 360–361  
    surface plasmon resonance (SPR), 360  
  secondary response and, 33  
Affinity constants, 24, 358  
Affinity maturation, 18, 127  
Affinity purification, 377–382  
  chromatography for cleanup and purification of antibody conjugates, 465  
  of modification state-specific antibodies, 379–381, 379f–380f, 382f  
  overview, 377  
  peptide affinity purification (protocol), 403–404  
  of peptide-specific antibodies, 378  
  of protein-specific antibodies, 378  
Affinity tag, 55, 56t, 58, 539  
Agarose, coupling antigens to, 63  
AH selection medium (recipe), 351  
AID (activation-induced deaminase), 17  
Aldehyde cross-linking sites for labeling antibody, 432, 433t  
Alignment algorithm, 51  
Alkaline phosphatase  
  in antibody capture assays, 210, 238–241  
  antibody conjugation to, 448  
  antigen detection on immunoblots, 519, 521–524  
  detecting alkaline phosphatase-labeled cells using BCIP-NBT, 719–720  
  using NABP-NF, 718  
  SEAP (secreted embryonic alkaline phosphatase), 338, 339f  
Alkaline phosphatase buffer (recipe), 523, 720  
Alkylation of proteins before running on a gel, 765  
Allelic exclusion, 17–18  
Allophycocyanin, 448  
Aluminum hydroxide adjuvant, 113, 114t, 116  
  preparation protocol, 148–149  
Alzheimer's disease, staining of amyloid plaques associated with, 430f  
American Type Culture Collection (ATCC), 309, 823  
Amido Black, 497  
Amines  
  cross-linking sites for labeling antibody, 431–432, 432t, 433t  
  labeling antibodies with NHS-LC-Biotin (protocol), 436–437  
Amino acids, 780t  
  codon usage, 783t–784t  
  mobility of residues, 52  
  substitutions, 786t  
Aminoethylcarbazole, detecting horseradish peroxidase-labeled cells using (protocol), 717  
Aminopterin, 205, 218, 316  
Amino-terminal regions, coupling to, 54  
Ammonium persulfate (APS), 491–492, 494  
Ammonium sulfate, saturated (recipe), 386  
Ammonium sulfate purification of antibodies, 372–373, 385–386  
Ammonium sulfate saturation tables, 778t  
Amphoteric detergents, 805, 806t  
Analytical ultracentrifugation, 361  
Anaphylactic shock, 122  
Anergy, 38  
Anesthesia. *See also specific anesthetic agents*  
  choice of, 112, 113t  
  depth of, 112, 138  
  protocols  
    for mice, rats, and hamsters, 136–138, 137f  
    for rabbits, 139–141  
Animals. *See also specific species*  
  humane treatment of, 821  
  immunizing, 107–199  
  killing mice, rats, and hamsters using carbon dioxide asphyxiation, 194–195  
  legal and moral considerations of use, 108–109  
Anion-exchange chromatography, 373–374  
Anionic detergents, 806t  
Annexin V, 749–750  
Antibiotics  
  addition to culture media, 304, 306t, 310, 312, 325, 340–341  
  resistance by *Mycoplasma*, 312, 312t, 313  
  ridding cell lines of contaminating microorganisms by antibiotics (protocol), 325–326  
  ridding cells of mycoplasma contamination using antibiotics and single-cell cloning (protocol), 340–341  
Antibody  
  characterizing, 353–370  
    antibody backbone, 361–364  
    effector domains, 362, 364  
    isotype, 361–362, 363t  
    antigen binding, 353–361  
      affinity, 358–361  
      antibody specificity, 353–354  
      antigenic epitopes, 354–357, 356f  
      complementarity determining regions (CDRs), 357–358  
    isotype determination of rodent-derived monoclonal antibodies using sandwich ELISA (protocol), 366–370

- Antibody (*Continued*)
- classes of
    - characteristics of, 13t
    - subclasses, 10
    - switching, 18f, 19, 39, 233–234
  - cross-reactivity, 6
  - defined, 2
  - diversity, 14
  - effector functions mediated by, 6–7, 7f
  - engineering (*see* Engineering antibodies)
  - labeling (*see* Labeling antibody)
  - monoclonal (*see* Monoclonal antibodies)
  - polyclonal (*see* Polyclonal antibodies)
  - purification (*see* Antibody purification)
  - recombinant (*see* Recombinant antibodies)
  - responses, 31–40
  - specificity, 23, 353–354
  - storage, 383–384
  - structure (*see* Antibody structure)
  - synthetic, 235–236
- Antibody–antigen complex
- affinity, 358–361
  - amount of complex formed, content of, 24
  - formation in immunoprecipitation, 538
  - structure of, 21–23, 22f
    - antigen binding site, 21–22, 22f
    - conformational changes, 23
    - epitopes, 22–23
    - noncovalent interactions, 23
    - specificity and, 23
- Antibody–antigen interactions, 21–28
- affinity, 24
  - avidity, 24–28, 25t, 26f–27f
  - structure of the antibody–antigen complex, 21–23, 22f
- Antibody binding
- controls for, 681
  - overview, 680–681
- Antibody-binding assay (protocol), simple
- multiplexed, 742–745, 744f, 744t
- Antibody capture
- capture or sandwich ELISA, 211f
  - direct ELISA, 211f
  - dot blots, 213, 213f
  - indirect ELISA, 211f
  - overview of, 209–213, 210f–211f, 212t, 213f
- protocols
- determining the class and subclass of a monoclonal antibody using antibody capture on antigen-coated plates, 294–296, 295f
  - determining the class and subclass of a monoclonal antibody using antibody capture on anti-immunoglobulin antibody-coated plates, 297–299
  - isotype determination of rodent-derived monoclonal antibodies using sandwich ELISA, 366–370
  - on nitrocellulose membrane
    - dot blot, 242–243
    - high-throughput western blot assay for hybridoma screening, 244–245
  - on permeabilized whole cells
    - immunofluorescence, 253–254
    - intracellular staining by flow cytometry/FACS, 249–250
  - in polyvinyl chloride wells
    - enzyme-linked detection (indirect ELISA), 238–239
    - enzyme-linked detection when immunogen is an immunoglobulin fusion protein (indirect ELISA to detect Ig fusion proteins), 240–241
    - on tissue sections (immunohistochemistry), 255–257
    - on whole cells
      - cell-surface binding (surface staining by flow cytometry/FACS), 246–248
      - cell-surface binding (surface staining by immunofluorescence), 251–252
- Antibody-coated antigens, injecting, 64
- Antibody complex, avidity of, 24–28, 25t, 26f–27f
- Antibody conjugates, cleanup and purification of, 464–468
- affinity chromatography, 465
  - desalting or buffer exchange using size-exclusion chromatography (protocol), 467–468
  - dialysis, 465–466
  - ion-exchange chromatography, 464–465
  - overview, 464–466, 464t
  - reversed-phase chromatography, 465
  - size-exclusion chromatography, 464, 464t, 467–468
- Antibody-dependent cellular cytotoxicity (ADCC) by flow cytometry (protocol), 751–754, 752f–753f
- Antibody footprinting, 356
- Antibody-producing cells, types of, 3f
- Antibody purification, 371–404
- affinity purification, 377–382
    - of modification state–specific antibodies, 379–381, 379f–380f, 382f
    - overview, 377
    - of peptide-specific antibodies, 378
    - of protein-specific antibodies, 378
  - large-scale antibody production, 382–383
  - overview, 371–384
    - affinity purification, 377–382, 403–404
    - anion-exchange chromatography, 373–374
    - chicken (IgY) antibodies, 375–376, 397–400
    - hydroxyapatite chromatography, 374–375
    - IgM purification, 376–377
    - immobilized metal affinity chromatography (IMAC), 375
    - ion-exchange methods, 374–375
    - isolation of a total IgG fraction, 372–373
      - ammonium sulfate precipitation, 372–373, 385–386
      - caprylic acid IgG isolation, 373, 387–388
    - large-scale antibody production, 382–383
    - Protein A chromatography, 375, 393–394
    - Protein G chromatography, 375, 395–396
    - purification of Fab and F(ab')<sub>2</sub> fragments, 376
- protocols, 385–404
- ammonium sulfate fractionation of antibodies, 385–386
  - conjugation of peptides to thiol-reactive gel, 401–402
  - high-pH DEAE chromatography, 391–392
  - isolation of IgY from chicken eggs: polyethylene glycol method, 399–400
  - isolation of IgY from chicken eggs: sodium sulfate method, 397–398
  - low-pH DEAE chromatography, 389–390
  - peptide affinity purification, 403–404
  - preparation of antibody using caprylic acid, 387–388
  - Protein A purification, 393–394
  - Protein G purification, 395–396
- Antibody responses, 31–40
- adjuvants and, 33–34
  - antigen presentation, 33–35, 35f
  - antigen type and, 33–34
  - B-cell activation, 33–34, 34f, 36–37, 37f, 38t
  - B cell differentiation and, 39–40, 40f
  - class II proteins and, 34–36
  - germinal centers and, 39
  - immune tolerance, 37–39
  - memory cells, 32–33
  - primary response, 32
  - secondary response, 32, 33
  - T-cell receptors and, 35–36, 37f
  - T follicular helper cell activation, 36, 37f
- Antibody sandwich ELISA
- immunometric (protocol), 651–657, 652f, 654t, 655f–656f
  - immunometric double-antibody (protocol), 658–660, 658f
- Antibody structure
- antigen-binding sites, 10–11, 11f, 12, 14
  - classes of antibodies and, 13t
  - constant regions, 12–13
  - diversity of, 14
  - Fab fragments, 10, 11f, 14
  - Fc fragments, 10–11, 11f
  - heavy chains, 10–14, 12f–13f
  - light chains, 10, 12, 12f–13f, 14
  - variable regions, 12–14
- Antigen
- coupling (*see* Coupling antigens)
- Antigen(s). *See also* Immunogen(s)
- binding to class II proteins, 35–36
  - bivalent binding to antigens immobilized on solid supports, 27f, 28
  - detection on immunoblots, 519–525
    - enzyme-based, 519, 521–524
    - with fluorochromes, 519–520, 525
  - modification, 61–64
  - nonresponders to, 36
  - phagocytosis and presentation, 33, 34–35, 35f
  - preparation using baculovirus expression system (protocol), 101–103
  - processing, 34
  - selection (*see* Antigen selection)
  - T-cell-dependent, 33
  - T-cell-independent, 34
- Antigen–antibody complex
- affinity, 358–361
  - amount of complex formed, content of, 24
  - formation in immunoprecipitation, 538
  - structure of, 21–23, 22f
    - antigen binding site, 21–22, 22f
    - conformational changes, 23
    - epitopes, 22–23
    - noncovalent interactions, 23
    - specificity and, 23

- Antigen binding, 353–361  
 affinity, 358–361  
 antibody specificity, 353–354  
 antigenic epitopes, 354–357, 356f  
 complementarity determining regions (CDRs), 357–358
- Antigen-binding sites  
 diversity of, 17  
 structure of, 10–11, 11f, 12, 14, 21–22, 22f
- Antigen capture  
 overview of, 210f, 213–214  
 protocols  
   on nitrocellulose membrane: reverse dot blot, 261–262  
   in solution: immunoprecipitation, 263  
   in 96-well plates (capture or sandwich ELISA), 258–260
- Antigen dialysis buffer (recipe), 80
- Antigen electrophoresis buffer (recipe), 80
- Antigenicity  
 defined, 2  
 predicting, 51–52
- Antigenicity prediction software, 51
- Antigen modification, 61–64  
 coupling antigens, 62–64  
   to beads, 63  
   bifunctional cross-linkers, 50t  
   haptens, 50  
   immune complexes as antigens, 63–64  
   to protein carriers, 62  
   to red blood cells, 63  
   with T-cell receptor–MHC-class II protein-binding sites, 62–63
- protocols  
 arsynyl coupling, 67–68  
 denaturation, 69  
 dinitrophenol coupling, 66
- Antigen-presenting cells (APCs), 2, 33–35, 35f  
 T follicular helper cell activation, 36, 37f  
 transfected dendritic cell immunizations (protocol), 104–106
- Antigen selection, 43–106  
 antigen modification, 61–64  
 immunogenicity, 44–49  
   failure of animal to respond, 46–47  
   polyclonal versus monoclonal antibodies, 47–48, 47t  
   properties of good immunogens, 45–46, 46t  
   selecting the antigen and, 48, 49t  
   synthetic class II–T-cell receptor sites, 47t
- protocols, 66–106  
 antigen preparation using baculovirus expression system, 101–103  
 autoradiography, 83–84  
 Coomassie Brilliant Blue staining, 73  
 copper chloride staining, 75  
 coupling antigens to red blood cells, 72  
 cross-linking peptides to KLH with maleimide, 85–86  
 electroelution of protein antigens from polyacrylamide gel slices, 79–80  
 electrophoretic transfer to nitrocellulose membranes, 81–82  
 fragmenting a wet gel slice, 77  
 GST-fusion protein preparation from bacteria, 87–88  
 His-fusion protein preparation from bacteria, 89–91  
 immune complex preparation for injection, 70–71
- live cell preparation for immunization, 100
- lyophilization of gel slice, 78
- MBP-fusion protein preparation from bacteria, 92–94
- mFc- and hFc-fusion protein preparation from mammalian cells, 97–99
- modifying antigens by arsynyl coupling, 67–68
- modifying antigens by denaturation, 69
- modifying antigens by dinitrophenol coupling, 66
- sarkosyl preparation of antigens from bacterial inclusion bodies, 95–96
- side-strip method, 76
- sodium acetate staining, 74
- transfected dendritic cell immunizations, 104–106
- questions to ask, 44
- sources of immunogens, 49–61, 49t  
 cDNA, 49t, 61  
 cell and tissue lysates, 49t, 59–60  
 haptens, 50  
 purified native proteins (pure antigens), 49t, 54–55  
 recombinant proteins, 49t, 55–59  
   advantages and disadvantages of use, 49t  
   from bacterial overexpression vectors, 55–56, 56t  
   from baculovirus overexpression vectors, 56  
   choosing between proteins and peptides, 57–59, 57t, 58t  
   from mammalian overexpression vectors, 56–57  
 synthetic peptides, 49t, 50–54  
   advantages and disadvantages of use, 49t, 51  
   carrier selection, 54  
   choosing over recombinant protein, 57–59  
   coupling strategy, 53–54  
   designing the peptide, 51–52  
   peptide design against highly homologous extracellular proteins, 53  
   peptide sequence choice, 52  
   size of peptide, 53
- Anti-immunoglobulin antibodies, avidity and, 27f, 28
- APCs. *See* Antigen-presenting cells
- Apoptosis assessment (protocol), 749–750, 750f
- APS (ammonium persulfate), 491–492, 494
- Arsynyl coupling, modifying antigens by (protocol), 67–68
- Ascites  
 induction  
   in BALB/c mice using myeloma cells (protocol), 183  
   induction and collection (protocol), 344–345  
   in mice, 129  
   using Freund's adjuvant (protocol), 182
- ridging cell lines of contaminating microorganisms by passage through mice (protocol), 328–329
- ridging cells of mycoplasma contamination by passage through mice (protocol), 342–343
- serial passage of tumors in mice, 345
- storing tissue culture supernatants and ascites (protocol), 347–348
- Asphyxiation, killing mice, rats, and hamsters using carbon dioxide (protocol), 194–195
- ATCC (American Type Culture Collection), 309, 823
- Atipamezole for anesthesia, 113t
- Attaching suspension cells to slides (protocols)  
 using cytocentrifuge, 688  
 using poly-L-lysine, 689
- Autoclave safety, 820
- Autoradiography, 55, 775  
 protocol, 83–84
- Autoreactivity, 6
- Avertin for anesthesia, 113t
- Avidin, 632
- 8-azaguanine selection, 205, 316–317, 349
- Azaserine, 205, 218, 316
- Azaserine/hypoxanthine (AH) selection medium, 316, 350–351
- ## B
- Back-fusing, 229
- Backscatter interferometry, 361
- Bacteria  
 biological safety procedures, 822–823  
 contamination of cell cultures, 230f, 277  
 overview, 309–310  
   ridging cell lines of by antibiotics (protocol), 325–326  
   ridging cell lines of by passage through mice (protocol), 328–329  
   ridging cell lines of with peritoneal macrophages (protocol), 327
- fusion protein preparation protocols  
 GST-fusion proteins, 87–88  
 His-fusion proteins, 89–91  
 MBP-fusion proteins, 92–94
- sarkosyl preparation of antigens from bacterial inclusion bodies (protocol), 95–96
- Bacterial expression, 809–818  
 maps  
   β-gal fusion vectors, 815f  
   gateway expression vectors, 817f  
   λgt11, 812f  
   pcDNA 3.1, 816f  
   pDEST 8, 818f  
   pDEST 15, 817f  
   pDEST 27, 817f  
   pET-SUMO, 816f  
   pFastBac1, 816f  
   plasmids, 813f–818f  
   Trp fusion vectors, 814f  
   T7 vectors, 813f
- screening for  
 chloroform lysis, 811  
 SDS lysis, 810  
 systems, 55–56, 57t, 58, 58t
- Bacterial overexpression vectors, preparing antigens from, 55–56, 56t, 57t
- Baculovirus expression system, 57t, 58–59, 58t  
 antigen preparation using (protocol), 101–103  
 materials, 101  
 protein expression and purification, 103  
 transfection of Sf9 cells and virus stock generation, 101–102  
 viral titer and plaque assay, 102–103  
 virus stock harvest and amplification, 102

- Baculovirus overexpression vectors, preparing  
antigens from, 56, 57f
- BAFF, 5, 31–32, 32f, 34, 34f, 38
- BAFF receptor (BAFF-R), 32, 32f, 38
- Bases  
disposal of, 82f  
safe handling of, 820, 823
- B-cell activating factor of the TNF family  
(BAFF), 5, 31–32, 32f, 34, 34f, 38
- B-cell activation, signals for, 33–34, 34f, 36–37, 37f, 38f
- B-cell receptor (BCR), 1, 2f, 4–5  
cross-linking, 36, 37f  
signaling and B-cell survival, 31–32, 32f
- B cells  
activation of, 1, 3  
described, 1–2  
differentiation, 3–4, 39–40, 40f, 45  
memory B cells, 3, 3f, 4, 32–33, 39–40, 40f  
plasma cells, 32, 39–40, 40f  
survival, signaling and, 31–32, 32f  
up-regulation of cytokine receptors, 37
- B-cell tolerance, 6, 38, 46
- B-cell tumors, 202
- BCIP-NBT, detecting alkaline phosphatase-labeled cells using (protocol), 719–720
- BCIP stock solution for AP (recipe), 523
- BCR. *See* B-cell receptor
- BeadBeater Cell Disruptor, 580, 582
- Beads  
bead-based enzyme-linked immunosorbant assay (ELISA), 642–643  
coupling antigens to, 63  
glass beads, lysing yeast cells with (protocol), 579–581  
using lysis buffer 2 without detergents (protocol), 582–584  
magnetic beads-immunoprecipitation, 540–541, 793
- Bentonite, coupling antigens to, 63
- Benzaldehyde, 377
- Berdoz primer set, 424
- $\beta$ -galactosidase detection in  
 $\beta$ -galactosidase-labeled cells  
using X-gal (protocol), 72f
- $\beta$ -gal fusion vectors, 815f
- $\beta$ -mercaptoethanol, 474
- $\beta$ -turns, 52
- Biacore AB, 360
- Bicinchoninic acid protein quantification, 792
- Bifunctional cross-linkers, 50t, 62
- Binding antibodies (protocols)  
to attached cells or tissues, 709–710  
to cells in suspension, 711–712
- Binding competition assays, 355, 356f
- Biolayer interferometry, 360
- Biological safety procedures, 822–823
- Bio-Rad (DEAE Affi-Gel Blue), 374–375
- Biotin, 681  
in antibody capture assays, 210  
labeling antibodies by biotinylation, 435–441  
labeling using biotin polyethylene oxide (PEO) iodoacetamide (protocol), 438–439  
labeling using Hydrazide-LC-biotin (protocol), 440–441  
labeling with NHS-LC-Biotin (protocol), 436–437  
size of, 435
- Bivalent binding  
of antibodies to polymeric antigens, 25, 26f  
to antigens immobilized on a solid phase, 27f, 28
- BLAST analysis, 51
- Blocking and incubation of immunoblots with antibodies, 509–518  
immunoblots prepared with immunoprecipitated protein antigens (immunoprecipitation/western blotting), 515–518  
immunoblots prepared with whole-cell lysates and purified proteins (straight western blotting), 510–514  
overview, 509
- Blocking buffer (recipe), 370
- Blocking buffers, ELISA, 635–636
- BLOTTO, 635  
bovine serum albumin (BSA)-based, 635  
casein-based, 636  
gelatin, 636  
protein-free, 636  
serum, 636
- Blocking/neutralizing or activating antibodies, screening for, 215
- Blocking nonspecific binding sites on the membrane for immunoblotting, 475–476, 476t
- Blocking reagents used for immunoblotting, 476–477
- Blocking solutions (recipe), 513, 517, 529
- Blood sampling  
methods of, 128t  
test bleeds, 127–129
- BLOTTO, 253–254, 509, 635
- B lymphocytes. *See* B cells
- BM Cyclin Mycoplasma Removal Kit, 341
- Boehringer Mannheim BM Cyclin Mycoplasma Removal Kit, 341
- Bolton-Hunter reagent, 461
- Boosts  
final before fusion, 218–220  
preparing myeloma cells for fusion, 219, 219f  
preparing partner cells for fusion, 218–219  
preparing splenocytes for fusion, 219–220, 219f–221f  
response to, 124  
timing of, 124
- Borate buffer (pH 8.0, 1 $\times$ ) (recipe), 595
- Borate buffer (pH 9.0, 1 $\times$ ) (recipe), 595
- Bordetella pertussis*, 113, 116, 148–149
- Bouin's fixative (recipe), 699
- Bovine serum albumin (BSA)  
based blocking buffers, 509, 635  
choosing as carrier, 54  
coupling antigens to, 62
- Bradford protein quantification, 789  
spot test, 790
- Bromochloroindoyl phosphate/nitro blue tetrazolium (BCIP-NBT), detecting alkaline phosphatase-labeled cells using (protocol), 719–720
- BSA. *See* Bovine serum albumin
- Buffer A for cross-linking antibodies to beads (recipe), 595, 599
- Buffer A for dounce homogenization (recipe), 573
- Buffer B for dounce homogenization (recipe), 573
- Buffer C for dounce homogenization (recipe), 574
- Buffer D for dounce homogenization (recipe), 574
- Buffer exchange using size-exclusion chromatography (protocol), 467–468
- Buffers, commonly used, 800t
- ## C
- Calcein AM, 751, 752f–753f, 754
- Caprylic acid, preparation of antibody using, 373, 387–388
- Capture ELISA. *See also* Sandwich ELISA  
antibody capture assay, 211f  
antigen capture assay, 214  
antigen capture in 96-well plates (protocol), 258–260
- Carbohydrates  
biotinylation antibodies using hydrazide-LC-biotin (protocol), 440–441  
cross-linking sites for labeling antibody, 432, 433t  
immunogen form for immunizing animals, 117t, 118t, 119
- Carbonate buffer (recipe), 650, 656, 660, 668, 673
- Carbon dioxide  
for anesthesia, 112  
killing mice, rats, and hamsters using carbon dioxide asphyxiation (protocol), 194–195
- Carbonyl cross-linking sites for labeling antibody, 431–432, 432t, 433t
- Carboxy-terminal sequences  
as antipeptide targets, 52  
coupling to, 54
- Carriers  
choosing appropriate, 54  
coupling antigens to protein carriers, 62  
cross-linking peptides to KLH with maleimide (protocol), 85–86
- Casein-based blocking buffers, 636
- Cationic detergents, 806t
- Cats  
binding characteristics of Protein A, Protein G, and Protein L, 212t  
IgG binding affinity for Proteins A, G, and L, 540t
- CBA (Cytometric Bead Assay), 232, 300
- CD4, 35
- CD40, 34
- CD40-CD40 L interaction, 37, 37f
- cDNA  
electroporation into *E. coli*, 418–419  
immunization, 125–126  
in mice, rats, and hamsters (protocol), 192–193, 193f  
as immunogen source, 49t, 61  
library construction, 417–420  
preparation  
in creation of recombinant antibodies using degenerate oligonucleotides (protocol), 407–409  
in creation of recombinant antibodies using phage display (protocol), 417–420  
in creation of recombinant antibodies using 5'-RACE (protocol), 410–411
- cDNA synthesis buffer (recipe), 411
- CDRs. *See* Complementarity determining regions
- Cell-based ELISA, direct and indirect (protocol), 661–665, 663f–664f
- Cell cultures, 304–309  
antibiotics for, 304, 306t, 310, 312, 325, 340–341  
checking cell lines for HPRT deficiency, 350–352  
contamination of, 309–313

- by bacteria, fungi, or yeast, 309–310, 325–329
- by mycoplasma, 310–313, 311t–312t, 330–343
- ricing cells of (protocols), 325–329, 340–343
- testing for (protocols), 330–339
- counting myeloma or hybridoma cells (protocol), 318–319, 319f
- detergent lysis of tissue culture cells (protocol), 565–567
- drug selection, 316–317, 349
- freezing cells for liquid nitrogen storage (protocol), 321–322
- media, 304–307, 305t–306t
- recovering cells from liquid nitrogen storage (protocol), 323–324
- sending and receiving hybridomas and myelomas, 309
- storage of, 309, 321–324
- supernatant collection, 314–315, 346
- supernatant storage, 347
- suppliers of media, 307t
- technique for, 307–308, 308f
- viability checks (protocol), 320
- Cell lysis for immunoprecipitation
  - denaturing lysis (protocol), 588–590
  - detergent lysis of animal tissues (protocol), 568–570
  - detergent lysis of tissue culture cells (protocol), 565–567
  - differential detergent lysis of cellular fractions (protocol), 575–578
  - freezing cell pellets for large-scale immunoprecipitation (protocol), 563–564
  - lysing yeast cells using a coffee grinder (protocol), 585–587
  - lysing yeast cells with glass beads (protocol), 579–581
    - using lysis buffer 2 without detergents (protocol), 582–584
  - lysis using dounce homogenization (protocol), 571–574
  - overview, 534–537
    - lysis buffers, 534–535
    - lysis of tissue, 536–537
    - lysis of tissue culture cells, 535–536
    - lysis of yeast, 537
    - protease inhibitor use, 535, 536t
  - protocols, 565–590
- Cell-permanent dye, 742–743
- Cell repositories, 309
- Cells
  - cultures of (*see* Cell cultures)
  - as immunogen source, 49t, 59–60
  - mouse antibody production (MAP) tested, 60
  - staining (*see* Cell staining)
- Cell smear
  - preparation (protocol), 690
  - preparing from tissue samples or cell cultures (protocol), 700
- Cell staining, 675–733
  - antibody choice for, 677–678, 677t
  - monoclonal antibodies, 677t, 678
  - polyclonal antibodies, 677–678, 677t
  - major constraints, 676
  - overview, 676
  - protocols, 686–733
    - attaching suspension cells to slides using cytocentrifuge, 688
    - using poly-L-lysine, 689
  - attaching yeast cells to slides using poly-L-lysine, 691–692
  - binding antibodies
    - to attached cells or tissues, 709–710
    - to cells in suspension, 711–712
  - cell smear preparation, 690
  - counterstaining, 729
  - detecting alkaline phosphatase-labeled cells
    - using BCIP-NBT, 719–720
    - using NABP-NF, 718
  - detecting  $\beta$ -galactosidase-labeled cells using X-gal, 721
  - detecting fluorochrome-labeled reagents, 722–724
  - detecting gold-labeled reagents, 725–726
  - detecting horseradish peroxidase-labeled cells
    - using aminoethylcarbazole, 717
    - using chloronaphthol, 716
    - using diaminobenzidine, 713–714, 714f
    - using diaminobenzidine and metal salts, 715
  - detecting iodine-labeled reagents, 727–728
  - embedding cultured cells in matrigel, 701–702
  - fixing attached cells
    - in organic solvents, 703–704
    - in paraformaldehyde or glutaraldehyde, 705–706
  - fixing suspension cells with paraformaldehyde, 707
  - general overview, 679–683
    - antibody binding, 680–681
    - detection, 681–683, 682t, 683t
    - fixation, 680
    - preparation of cells and tissues, 679–680
  - growing adherent cells
    - on coverslips or multiwell slides, 686
    - on tissue culture dishes, 687
  - heat-induced epitope retrieval, 698–699
  - lysing yeast, 708
  - mounting cell or tissue samples
    - in DPX, 730
    - in Gelvatol or Mowiol, 731
  - photographing samples, 733
  - preparing cell smears from tissue samples or cell cultures, 700
  - preparing frozen tissue sections, 693–695
  - preparing paraffin tissue sections, 696–697
  - strength of antibody binding, 25t
  - troubleshooting background problems, 683–684
- Cell-surface binding
  - surface staining by flow cytometry/FACS, 246–248
  - surface staining by immunofluorescence, 251–252
- Cell surface receptor internalization, 216f
- Chasing medium (recipe), 556
- Chemically defined medium, 304, 307t
- Chemicals, properties of common hazardous, 823–824
- Chemifluorescent substrates, ELISA, 638–639
- Chemiluminescence
  - antigen detection on immunoblots, 522
  - reprobing membranes after immunoblotting, 526
- substrates, ELISA, 638
- Chickens
  - binding characteristics of Protein A, Protein G, and Protein L, 212t
  - IgY antibodies, 375–376, 397–400
    - isolation of IgY from chicken eggs: polyethylene glycol method (protocol), 399–400
    - isolation of IgY from chicken eggs: sodium sulfate method (protocol), 397–398
- ChIP (chromatin immunoprecipitation). *See* Immunoprecipitation, chromatin
- Chloroauric acid, 455, 459–460
- Chloroform lysis, screening for bacterial expression by, 811
- Chloronaphthol, detecting horseradish peroxidase-labeled cells using (protocol), 716
- Chromatin immunoprecipitation (ChIP). *See* Immunoprecipitation, chromatin
- Chromatography. *See specific chromatography types*
- Chromogenic antigen detection on immunoblots, 477, 522
- Chromogenic substrates
  - ELISA, 637–638
  - yielding water-insoluble products, 797t
  - yielding water-soluble products, 797t
- Chromosome loss in hybridomas, 205
- Cibacron Blue F3GA, 375
- Cimetidine, 116
- Citraconic anhydride, 62
- Citrate binding buffer (recipe), 98
- Citrate elution buffer (recipe), 99
- Classes of antibodies
  - characteristics of, 13t
  - subclasses, 10
  - switching, 18f, 19, 39, 233–234
- Class II protein
  - antigen binding to, 35–36
  - diversity of, 36
  - structure, 34–35
- Class switching, 18f, 19, 39, 233–234
- Cleanup and purification of antibody conjugates, 464–468
  - affinity chromatography, 465
  - desalting or buffer exchange using size-exclusion chromatography (protocol), 467–468
  - dialysis, 465–466
  - ion-exchange chromatography, 464–465
  - overview, 464–466, 464t
  - reversed-phase chromatography, 465
  - size-exclusion chromatography, 464, 464t, 467–468
- Clonal deletion, 5f, 6, 38
- Clonal dominance, 127
- Clonal selection, 4–6, 5f
- Cloning
  - single-cell cloning by growth in soft agar, 288–290
  - single-cell cloning by limiting dilution, 286–287
- cMyc epitope tag, 539
- Codon-optimized bacteria, 56
- Codon usage, 783t–784t
- Coffee grinder, lysing yeast cells using (protocol), 585–587
- Coimmunoprecipitation, 532

- Colloidal gold, 455, 459–460  
 Colorimetric substrates. *See* Chromogenic substrates  
 Commercial liquids, concentrations of, 803t  
 Competition assays, for epitope binding, 355, 356f  
 Competitive ELISA  
   direct (protocol), 666–669, 666f  
   indirect (protocol), 670–673, 670f, 673f  
 Complementarity determining regions (CDRs), 14, 17–18, 17f14, 22, 22f  
   described, 357  
   sequencing, 357–358  
 Complete Freund's adjuvant, 113, 114, 142  
 Conjugation of peptides to thiol-reactive gel, 401–402  
 Contamination  
   of cell cultures, 309–313  
     by bacteria, fungi, or yeast, 309–310, 325–329  
     by mycoplasma, 310–313, 311t–312t, 330–343  
     ridding cells of (protocols), 325–329, 340–343  
     testing for (protocols), 330–339  
   of a cloned line, 230–231  
   in fusion wells, 229–230  
 Coomassie Blue G, 55  
 Coomassie Brilliant Blue staining, 73, 497  
   maximal sensitivity, 769  
   quick method, 768  
   standard method, 768  
 Coomassie spot test for protein quantification, 790  
 Copper chloride, 55  
 Copper staining of gels, 75, 772  
 Counterstaining cells (protocol), 729  
 Counting myeloma or hybridoma cells (protocol), 318–319, 319f  
 Counting <sup>32</sup>P or <sup>125</sup>I from polyacrylamide gel slices, 767  
 Counting <sup>35</sup>S, <sup>14</sup>C, <sup>3</sup>H from polyacrylamide gel slices, 767  
 Coupled antigens, pH of, 54  
 Coupling  
   choosing strategy for, 53–54  
   multiple sites, 54  
 Coupling antigens, 62–64  
   to beads, 63  
   bifunctional cross-linkers, 50t  
   haptens, 50  
   immune complexes as antigens, 63–64  
   to protein carriers, 62  
   protocols  
     coupling to red blood cells, 72  
     modifying antigens by arsynyl coupling, 67–68  
     modifying antigens by dinitrophenol coupling, 66  
   to red blood cells, 63  
   with T-cell receptor–MHC-class II protein-binding sites, 62–63  
 Coverslips, growing adherent cells on (protocol), 686  
 Cows  
   binding characteristics of Protein A, Protein G, and Protein L, 212t  
   IgG binding affinity for Proteins A, G, and L, 540t  
 CpG DNA, Magic Mouse adjuvant and, 115, 146–147  
 Critical micelle concentration, 804  
 Cross-linkers  
   bifunctional, 50t, 62  
   removal of, 62  
   selection for labeling antibody, 431–433, 432t, 433t  
     amines/carbonyls, 431–432, 432t, 433t  
     carbohydrates (aldehydes), 432, 433t  
     sulfhydryls, 432t, 433, 433t  
 Cross-linking peptides to KLH with maleimide (protocol), 85–86  
 Cross-reactivity, antibody, 6  
 Cutting devices, safe handling of, 821  
 Cyanogen bromide, 377  
 Cyclophosphamide, in subtractive immunization, 60  
 Cy5-phycoerythrin, labeling antibodies with, 452–454  
 Cysteine  
   maleimide linkage and, 54  
   metabolic labeling of antigens with [<sup>35</sup>S] methionine (protocol), 546–551  
 Cyto centrifuge, attaching suspension cells to slides using (protocol), 688  
 Cytokines, 37, 38t  
 Cytometric Bead Assay (CBA), 232, 300  
 Cytotoxicity  
   antibody-dependent cellular cytotoxicity (ADCC) by flow cytometry (protocol), 751–754, 752f–753f  
   complement-dependent cytotoxicity assay (protocol), 747–748, 748f
- ## D
- DAB. *See* Diaminobenzidine  
 DAB substrate solution for HRP (recipe), 523  
 DAPI, properties of, 723t  
 David's life chart II, 788t  
 DCC (dicyclohexylcarbodiimide), 431–432  
 DEAE Affi-Gel Blue (Bio-Rad), 374–375  
 DEAE chromatography  
   anion-exchange chromatography, 373–374  
   high-pH DEAE chromatography (protocol), 391–392  
   low-pH DEAE chromatography (protocol), 389–390  
 Decoy immunization, 60  
   for mice, rats, and hamsters (protocol), 190  
 Denaturation, modifying antigens by (protocol), 69  
 Denaturing lysis (protocol), 588–590  
 Dendritic cells, 2, 2f, 4, 33–34, 34f  
   transfected dendritic cell immunizations (protocol), 104–106  
 Desalting or buffer exchange using size-exclusion chromatography (protocol), 467–468  
 Detection of stained cells  
   alkaline phosphatase, 683t, 718–720  
    $\beta$ -galactosidase, 683t, 721  
   double labeling, 682–683  
   enzyme-labeled reagents, 681, 682t, 683, 683t  
   fluorochrome-labeled reagents, 682, 682t, 722–724  
   gold-labeled reagents, 682, 682t, 725–726  
   horseradish peroxidase, 683t, 713–717  
   iodine-labeled reagents, 682, 682t, 727–728  
   overview, 681–683  
   protocols  
     detecting alkaline phosphatase-labeled cells  
       using BCIP-NBT, 719–720  
       using NABP-NF, 718  
     detecting  $\beta$ -galactosidase-labeled cells  
       using X-gal (protocol), 721  
     detecting fluorochrome-labeled reagents, 722–724  
     detecting gold-labeled reagents, 725–726  
     detecting horseradish peroxidase-labeled cells  
       using aminoethylcarbazole, 717  
       using chloronaphthol, 716  
       using diaminobenzidine, 713–714, 714f  
       using diaminobenzidine and metal salts, 715  
     detecting iodine-labeled reagents, 727–728  
 Detergent lysis  
   of animal tissues (protocol), 568–570  
   differential of cellular fractions (protocol), 575–578  
   of tissue culture cells (protocol), 565–567  
 Detergents  
   amphoteric, 805, 806t  
   critical micelle concentration, 804  
   described, 804  
   hydrophile-lipophile balance (HLB), 804  
   ionic, 805, 806t  
   micelle molecular weight, 804  
   nonionic, 805, 806t  
   properties of commonly used, 806t  
   removal of, 805  
 Developing solution for AP (recipe), 239, 241  
 Developing solution for Strep-AP (recipe), 259  
 Developmental Studies Hybridoma Bank, 309  
 Dialysis for cleanup and purification of antibody conjugates, 465–466  
 Dialysis tubing preparation, 795  
 Diaminobenzidine (DAB)  
   detecting horseradish peroxidase-labeled cells using (protocol), 713–714, 714f  
   detecting horseradish peroxidase-labeled cells using diaminobenzidine and metal salts (protocol), 715  
   substrate for horseradish peroxidase, 519, 522  
 Diaminobenzidine (DAB) solution (recipe), 257  
 Dibutyl phthalate  
   mounting cell or tissue samples in DPX (protocol), 730  
 Dicyclohexylcarbodiimide (DCC), 431–432  
 Diethylene triamine pentaacetic acid (DTPA), 455  
 Digital imaging, 733  
 Digitonin, in differential detergent lysis of cellular fractions protocol, 575–576  
 Digitonin extraction buffer (recipe), 577  
 Dimethyl pimelimidate (1 $\times$ ) (recipe), 596  
 Dimethyl pimelimidate (DMP), crossing antibodies to beads using, 591, 592f, 593–596  
 Dimethyl sulfoxide (DMSO), 55, 309  
 Dinitrophenol coupling, modifying antigens by (protocol), 66  
 Direct ELISA  
   advantages and disadvantages, 633f  
   antibody capture assay, 211f  
   cell-based ELISA, 661–665, 663f–664f  
   direct competitive ELISA, 666–669, 666f  
   sandwich ELISA, 652f  
 Disposal  
   general cautions, 819–821  
   of laboratory waste, 821  
 Distrene  
   mounting cell or tissue samples in DPX (protocol), 730

- Disuccinimidyl glutarate (0.5 M) (recipe), 627  
 Disuccinimidyl glutarate (DSG), 625–626  
 Disuccinimidyl subpimelimidate (DSS), crossing antibodies to beads using, 591, 592f, 597–600  
 Disulfide bonding, 57  
 Dithiothreitol (DTT), 474  
 D-10 medium (recipe), 277  
 DMEM (Dulbecco's modified Eagle's medium), 304, 305t–306t  
 DMP (dimethyl pimelimidate), crossing antibodies to beads using, 591, 592f, 593–596  
 DMSO (dimethyl sulfoxide), 55, 309  
 DMSO (dimethyl sulfoxide), for storage of hybridomas, 309  
 DNA. *See also* cDNA  
   CpG, 115, 146–147  
   genetic immunization, 125–126  
   rearrangements  
     heavy-chain genes, 15–16, 16f  
      $\kappa$  gene and, 14–15, 15f  
      $\lambda$  gene and, 15, 16f  
 DNA blotting, 470  
 DNA loading buffer (6 $\times$ ) (recipe), 622  
 DNASTAR software package, 51  
 DNBS (sodium dinitrobenzene sulfonic acid), 66  
 DNP. *See* Dinitrophenol  
 DOC (sodium deoxycholate), 535  
   in differential detergent lysis of cellular fractions protocol, 575–576  
 Dogs  
   binding characteristics of Protein A, Protein G, and Protein L, 212t  
   IgG binding affinity for Proteins A, G, and L, 540t  
 Donkey  
   IgG binding affinity for Proteins A, G, and L, 540t  
 DOTA (1,4,7,10-tetraazacyclododecane-tetraacetic acid), 455, 457  
 Dot blots  
   antibody capture assay, 213  
   antibody capture on nitrocellulose membrane (protocol), 242–243  
   antigen capture assay: reverse dot blots (protocol), 214  
   apparatus, 213f  
 Dot plots, 736, 736f  
 Dounce homogenization, lysis using (protocol), 571–574  
 DPX, mounting cell or tissue samples (protocol), 730  
 Drug selection, 218  
   unfused myeloma cells eliminated by, 205  
 Drying gels, 773  
 DSG (disuccinimidyl glutarate), 625–626  
 DSS (disuccinimidyl subpimelimidate), crossing antibodies to beads using, 591, 592f, 597–600  
 DTPA (diethylene triamine pentaacetic acid), 455  
 DTT (dithiothreitol), 474  
 Dulbecco's modified Eagle's medium (DMEM), 304, 305t–306t  
 Dulbecco's phosphate-buffered saline (pH 7.2, 1 $\times$ ) (recipe), 599  
 Dyes, hazards of, 823
- E**
- EBC lysis buffer (recipe), 622  
 ECF buffer 1 $\times$  (recipe), 284  
 EDC (ethyl(dimethylaminopropyl) carbodiimide), 431–432  
 Effector domains, 362, 364  
 EIA. *See* Enzyme immunoassay  
 Electro cell fusion (protocol), 281–285, 282f  
   materials, 281  
   method, 282–283  
     performing fusion, 283  
     preparation of cells for fusion, 282–283  
     purification of B cells from lymph nodes by negative selection, 282  
   recipes, 284–285  
   setup, 282f  
   troubleshooting, 283–284  
 Electroelution of protein antigens from polyacrylamide gel slices (protocol), 79–80  
 Electron microscopy  
   labeling antibodies with colloidal gold (protocol), 459–460  
 Electrophoretic transfer to nitrocellulose membranes (protocol), 81–82  
 Electrophoresis, 755–775. *See also* Polyacrylamide gel electrophoresis  
   alkylation of proteins before running on a gel, 765  
   autoradiography, 775  
   Coomassie Brilliant Blue staining  
     maximal sensitivity, 769  
     quick method, 768  
     standard method, 768  
   copper staining of gels, 772  
   counting  $^{32}\text{P}$  or  $^{125}\text{I}$  from polyacrylamide gel slices, 767  
   counting  $^{35}\text{S}$ ,  $^{14}\text{C}$ ,  $^3\text{H}$  from polyacrylamide gel slices, 767  
   drying gels, 773  
   fixing gels, 773  
   fluorography, 775  
   partial proteolytic peptide maps, 760–761  
   PPO fluorography, 766  
   rehydrating dried polyacrylamide gels, 774  
   SDS-polyacrylamide gel electrophoresis, 755–759  
   silver staining of gels  
     ammoniacal silver staining, 770  
     neutral silver staining, 771  
   two-dimensional isoelectric focusing/  
   SDS-polyacrylamide gel electrophoresis, 762–764  
 Electrophoretic transfer, 55  
   semi-dry, 499–502, 500f  
   wet, 503–506  
 Electroporation of cDNA into *E. coli*, 418–419  
 ELISA. *See* Enzyme-linked immunosorbent assay  
 ELISpot assay, 651  
 Elution buffer (recipe), 623  
 Embedding cultured cells in matrigel (protocol), 701–702  
 EMD Millipore, 409  
 Engineering antibodies, 405–428  
   creation of recombinant antibodies using degenerate oligonucleotides (protocol), 407–409  
   discussion, 408–409  
   materials, 407–408  
   method, 408  
   creation of recombinant antibodies using phage display (protocol), 412–421  
   discussion, 420  
   materials, 412–414  
   method, 414–420  
   amplification of gene III, 415  
   construction of cDNA library, 417–420, 419t  
   construction of Gene III-kappa c-region insert and ligation into pPDS, 415–416  
   construction of pLINK and pFABC, 416–417  
   construction of pPDS vector, 414  
   primer list, 419t  
   creation of recombinant antibodies using 5'-RACE (protocol), 410–411  
   materials, 410  
   method, 410–411  
   recipe, 411  
   modification of antibody function by mutagenesis (protocol), 422–423  
   materials, 422  
   method, 423  
   rescue strategy for nonviable hybridomas (protocol), 424–427  
   materials, 424–425  
   method, 425–427  
 Enzymatic detection of immunoblots, 477  
 Enzyme immunoassay (EIA), 629. *See also* Enzyme-linked immunosorbent assay  
 Enzyme-linked immunosorbent assay (ELISA), 629–673. *See also specific ELISA types*  
   antibody detection and quantification, 632  
   antigen detection and quantification, 630–631  
   bead-based, 642–643  
   blocking buffers, 635–636  
   BLOTTO, 635  
   bovine serum albumin (BSA)-based, 635  
   casein-based, 636  
   gelatin, 636  
   protein-free, 636  
   serum, 636  
   checkerboard titration of antigen and antibody by serial dilution, 654t  
   choosing a protocol, 631t  
   deciding where to start, 630  
   ELISpot assay, 651  
   epitope binding competition assays, 355, 356f  
   host cell protein (HCP), 632, 655–656  
   indirect versus direct detection, 632, 633f  
   isotyping and, 361, 366–370  
   isotyping template for, 295f, 298f  
   to measure antibody affinity, 358–359  
   microtiter plate selection, 632–635, 634f, 634t  
   multiplexing flow cytometry and, 737  
   overview, 629–643  
   parameters, 639–640, 639f  
   protocols, 644–673  
     direct and indirect cell-based ELISA, 661–665, 663f–664f  
     direct competitive ELISA, 666–669, 666f  
     immunometric antibody sandwich ELISA, 651–657, 652f, 654t, 655f–656f  
     immunometric double-antibody sandwich ELISA, 658–660, 658f  
     immunometric indirect ELISA, 644–650, 644f–645f, 647t–649t  
     indirect competitive ELISA, 670–673, 671f, 673f  
     reporter-labeled secondary antibodies, 636–637, 637t

- Enzyme-linked immunosorbant assay (ELISA)  
(*Continued*)  
screening for phospho-specific antibodies, 214  
substrates, 637–639  
  chemifluorescent, 638–639  
  chemiluminescent, 638  
  chromogenic (colorimetric), 637–638  
troubleshooting guide, 647t–648t  
types, 642–643  
validation parameters, 640–642, 640t  
  accuracy, 641  
  limit of detection (LoD), 641  
  linearity, 641  
  precision, 640  
  quantification limit (LoQ), 641  
  range, 642  
  sensitivity, 641  
  specificity, 642  
  wash buffers, 636
- Enzyme-linked immunosorbant spot (ELISpot)  
assay, 651
- Epinephrine, for anaphylactic shock, 122
- Epitope  
  amino acid mobility an, 52  
  antibody specificity and, 353–354  
  binding competition assays, 355, 356f  
   $\beta$ -turns in, 52  
  choosing between recombinant proteins and  
  peptides for immunogen  
  production, 57  
  conformational, 354–355  
  described, 6, 354–357  
  discontinuous, 57  
  functional, 355  
  heat-induced epitope retrieval (protocol),  
  698–699  
  linear, 354–355  
  mapping, 355–357  
  processed antigen fragments, 35–36  
  size of, 22, 53  
  structural, 355  
  structure of, 22–23  
  tags in immunoprecipitation, 539
- Epitope retrieval, heat-induced (protocol),  
698–699
- Epstein-Barr virus (EBV), 234
- Equilibrium dialysis to obtain affinity constants  
for antibodies, 358
- Escherichia coli*  
  electroporation of cDNA into, 418–419  
  for recombinant protein expression, 58, 58t
- Ethanolamine, 593–594
- Ethanolamine (1 $\times$ ) (recipe), 596
- Ethyl(dimethylaminopropyl) carbodiimide  
(EDC), 431–432
- Europium, labeling antibodies using, 457–458
- Euthanasia  
  killing mice, rats, and hamsters using carbon  
  dioxide asphyxiation (protocol),  
  194–195
- ExactSTART, 410
- ExPASy, 51
- Exsanguination, 129
- Extracellular proteins, designing peptides against  
highly homologous, 53
- F**
- Fab, 14  
  fragments, 10, 11f  
  purification of Fab and F(ab')<sub>2</sub>  
  fragments, 376
- FACS  
  intracellular staining by, 249–250  
  isotyping and, 361  
  surface staining by flow cytometry/FACS,  
  246–248
- FACS buffer (recipe), 745
- FastPrep Cell Disruptor, 580
- Fast protein liquid chromatography (FPLC),  
373–374
- FBS. *See* Fetal bovine serum
- Fc-binding proteins, human isotype classes and,  
363t
- Fc domains, immunoglobulin isotypes and,  
363–364, 363f
- Fc fragments, 10–11, 11f
- FcRn (neonatal Fc receptor), 236
- Feeder cells  
  fibroblast feeder cell culture preparation  
  (protocol), 271  
  splenocyte feeder cell culture preparation  
  (protocol), 269–270
- Feeder plate preparation, 218  
  myeloma cell, 267–268  
  peritoneal macrophage, 266
- Fentanyl/droperidol for anesthesia, 112
- Fentanyl/fluanisone for anesthesia, 112
- Fentanyl for anesthesia, 112, 140
- Fetal bovine serum (FBS)  
  addition to cell culture media, 304  
  screening for good batches of, 264–265
- FiberCell Systems, 315, 315f
- Fibroblast feeder cell culture preparation  
(protocol), 271
- 5'-RACE, creation of recombinant antibodies  
using (protocol), 410–411  
  materials, 410  
  method, 410–411  
  recipe, 411
- Fixation, 680  
  fixing attached cells (protocols)  
  in organic solvents, 703–704  
  in paraformaldehyde or glutaraldehyde,  
  705–706  
  fixing suspension cells with paraformaldehyde  
  (protocol), 707
- of gels, 773  
overview of, 680  
unmasking hidden epitopes with proteases,  
680
- FLAG  
  epitope tag, 539, 607  
  tandem immunoaffinity purification using  
  anti-FLAG and anti-HA  
  antibodies (protocol), 607–612
- Flow cytometry, 735–754  
  data plots, 736–737, 736f  
  determining the class and subclass of a  
  monoclonal antibody using  
  (protocol), 300–301  
  equipment, 735  
  fluorochrome excitation and emission  
  spectra, 736, 736f  
  intracellular staining by, 249–250  
  multiplexing, 737, 740  
  overview of, 735–737  
  plate-based, 738, 739t  
  protocols, 742–754  
  antibody-dependent cellular cytotoxicity  
  (ADCC), 751–754, 752f–753f  
  apoptosis assessment, 749–750, 750f  
  complement-dependent cytotoxicity  
  assay, 747–748, 748f
- simple multiplexed antibody-binding  
  assay, 742–745, 744f, 744t  
  screening assay design and optimization,  
  738, 740  
  surface staining by flow cytometry/FACS,  
  246–248
- Fluorescein  
  detecting fluorochrome-labeled reagents in  
  stained cells (protocol), 722–724  
  labeling antibodies using NHS-fluorescein  
  (protocol), 444–445  
  properties of, 723t
- Fluorescence. *See also* Flow cytometry; *specific  
protocols*  
  chemifluorescent substrates, ELISA,  
  638–639  
  immunofluorescence  
  antibody capture on permeabilized  
  whole cells, 253–254  
  surface staining by, 251–252  
  quenching, 733
- Fluorescent proteins  
  protein–antibody conjugate formation,  
  448–449, 452–454
- Fluorescent resonance energy (FRET) dyes,  
448–449, 452–453
- Fluorochromes. *See also* Fluorophores  
  choosing correct, 723–724  
  detecting fluorochrome-labeled reagents in  
  stained cells, 722–724  
  for detection of antigen on immunoblots,  
  519–520, 525  
  excitation and emission spectra of, 723t, 736,  
  736f  
  fluorochrome-labeled secondary reagents for  
  immunoblotting, 478  
  fluorochrome-labeled streptavidin, 516–517  
  properties of, 723t  
  reprobing membranes after immunoblotting,  
  526
- Fluorography, 766, 775
- Fluorophores. *See also* Fluorochromes  
  labeling antibodies with, 442–447  
  overview, 442–443, 442t  
  using a maleimido dye (protocol),  
  446–447  
  using NHS-fluorescein (protocol),  
  444–445  
  list of fluorophores, 442t
- Footpad immunization, 123  
  of mice, rats, and hamsters (protocol),  
  168–169, 169f
- Footprinting, antibody, 356
- Formaldehyde, for cross-linking proteins to  
DNA, 614, 617–618, 625–626
- Formaldehyde solution (11%) (recipe), 623
- FPLC (fast protein liquid chromatography),  
373–374
- Fragmenting a wet gel slice (protocol), 77
- Freezing  
  cell pellets for large-scale  
  immunoprecipitation (protocol),  
  563–564  
  cells for liquid nitrogen storage, 321–322  
  for storage of hybridomas, 309
- FRET (fluorescent resonance energy) dyes,  
448–449, 452–453
- Freund's adjuvant, 113, 114–115  
  advantages and disadvantages of, 114t  
  ascites induction using Freund's adjuvant  
  (protocol), 182
- Complete, 113, 114, 142



- Incomplete, 114  
preparation protocol, 142–143, 143f
- Frozen tissue sections, preparing (protocol), 693–695
- Functional assays, 215–216
- Functional epitope mapping methods, 355–357
- Functional screens, 210f, 214–215  
for blocking/neutralizing or activating antibodies, 215  
for internalizing antibodies, 215, 216f  
for phospho-specific antibodies, 214–215
- Fungi contamination of cell cultures, 230f, 309–310  
overview, 309–310  
ridding cell lines of by antibiotics (protocol), 325–326  
ridding cell lines of by passage through mice (protocol), 328–329  
ridding cell lines of with peritoneal macrophages (protocol), 327
- Fusion protein preparation protocols  
GST-fusion proteins, 87–88  
His-fusion proteins, 89–91  
MBP-fusion proteins, 92–94  
mFc- and hFc-fusion protein preparation from mammalian cells, 97–99
- Fusions  
back-fusing, 229  
overview of, 220–222  
polyethylene glycol, 222  
Sendai virus, 221  
protocols  
electro cell, 281–285, 282f  
polyethylene glycol, 274–278  
by sendai virus, 279–280
- Fusion selection (HAT) medium (recipe), 268
- ## G
- Gas containers, safe handling of, 820
- Gateway expression vectors, 817f
- Gelatin, for ELISA blocking, 636
- Gel fragments, processing, 55
- Gels  
drying, 773  
fixing, 773  
rehydrating dried, 774  
transfer of proteins from gels to membranes, 497–508  
overview, 497  
semi-dry electrophoretic transfer (protocol), 499–502, 500f  
staining the blot for total protein with Ponceau S (protocol), 507–508  
wet electrophoretic transfer (protocol), 503–506
- Gel slice(s)  
counting <sup>32</sup>P or <sup>125</sup>I from polyacrylamide gel slices, 767  
counting <sup>35</sup>S, <sup>14</sup>C, <sup>3</sup>H from polyacrylamide gel slices, 767  
electroelution of protein antigens from polyacrylamide (protocol), 79–80  
fragmenting (protocol), 77  
lyophilization (protocol), 8
- Gelvatol, mounting cell or tissue samples in (protocol), 731
- Gene III  
amplification of, 415  
construction of Gene III-kappa c-region insert and ligation into pPDS, 415–416
- Gene knockout, immune response weakened by, 53
- Genetic code, 781t  
mitochondrial, 782t
- Genetic immunization, 125–126
- GenomOne Kits, 279
- Gentamicin, addition to culture media, 304, 306t
- GERBU adjuvant, 116
- Germinal centers, 39
- GFP (green fluorescent protein), 448
- Glass beads, lysing yeast cells with (protocol), 579–581  
using lysis buffer 2 without detergents (protocol), 582–584
- Glutaraldehyde, 432  
fixing attached cells in (protocol), 705–706
- Glutathione-S-transferase (GST), 55, 56t  
as affinity tag, 539  
GST-fusion protein preparation from bacteria (protocol), 87–88
- Glycerol  
for antibody storage, 383  
for hybridoma storage, 309
- Glycine, 597, 599, 608, 609
- Glycoproteins, antigen receptors as, 5
- Goats  
binding characteristics of Protein A, Protein G, and Protein L, 212t  
IgG binding affinity for Proteins A, G, and L, 540t
- Gold  
colloidal, 455, 459–460  
detecting gold-labeled reagents, 725–726
- Green fluorescent protein (GFP), 448
- Growing adherent cells (protocols)  
on coverslips or multiwell slides, 686  
on tissue culture dishes, 687
- Growing hybridomas. *See* Hybridomas, growing
- GST. *See* Glutathione-S-transferase
- GST elution buffer, pH 8.0 (recipe), 88
- GST-fusion protein preparation from bacteria (protocol), 87–88
- GST lysis buffer (recipe), 88
- Guanidine-chloride stripping buffer (recipe), 529
- Guinea pigs  
antigen dose for, 116  
binding characteristics of Protein A, Protein G, and Protein L, 212t  
bleed sample amount from, 110  
IgG binding affinity for Proteins A, G, and L, 540t
- ## H
- HA (hemagglutinin)  
epitope tag, 539, 607  
tandem immunoaffinity purification using anti-FLAG and anti-HA antibodies (protocol), 607–612
- Haloacetyl cross-linkers, 433, 433t
- Ham's F-12 medium, 305t–306t
- Hamsters  
administering anesthesia to (protocol), 136–138, 137f  
antigen dose for, 116, 118t  
bleed sample amount from, 110  
cDNA immunization (protocol), 192–193, 193f  
decoy immunization for (protocol), 190  
footpad or hock immunization (protocol), 168–169, 169f  
IgG binding affinity for Proteins A, G, and L, 540t
- injection routes for, 120t  
killing using carbon dioxide asphyxiation (protocol), 194–195  
lymph node harvesting from (protocol), 198–199, 199f  
repetitive immunization at multiple sites (RIMMS) (protocol), 188  
spleen harvesting from (protocol), 196–197, 197f  
standard immunization (protocol), 184–185  
subtractive immunization (protocol), 189  
test bleeds in, 128–129
- Haptens, 36, 50  
cross-linking peptides to KLH with maleimide (protocol), 85–86
- Harvesting tissue protocols, 194–199  
killing mice, rats, and hamsters using carbon dioxide asphyxiation, 194–195  
lymph node harvesting from mice, rats, and hamsters, 198–199, 199f  
spleen harvesting from mice, rats, and hamsters, 196–197, 197f
- HAT fusion medium (recipe), 278, 284
- HAT (hypoxanthine/aminopterin/thymidine) selection, 217, 218, 224, 267
- HAT selection medium (recipe), 351
- Hazardous chemicals, properties of common, 823–824
- HCP (host cell protein) ELISA, 632
- Heat-induced epitope retrieval (protocol), 698–699
- Heavy-chain gene, DNA rearrangements and, 15–16, 16f
- Heavy metal chelators, 455
- HEK-Blue Detection medium, 338–339, 339f
- Helper T cells, 35, 36
- Hemagglutinating virus of Japan (HVJ), 221, 279–280. *See also* Sendai virus
- Hemagglutinin (HA)  
epitope tag, 539, 607  
tandem immunoaffinity purification using anti-FLAG and anti-HA antibodies (protocol), 607–612
- Hemocytometer, 318–319, 319f
- Heterokaryon, 205
- High-pressure liquid chromatography (HPLC), 373–374
- High-throughput functional assays  
antibody-dependent cellular cytotoxicity (ADCC), 751–754, 752f–753f  
apoptosis assessment, 749–750, 750f  
complement-dependent cytotoxicity assay, 747–748, 748f
- High-throughput western blot assay for hybridoma screening (protocol), 244–245
- Hinge region, antibody, 10, 11f
- His6 epitope tag, 539
- His-fusion binding buffer, pH 7.4 (recipe), 90
- His-fusion elution buffer, pH 7.4 (recipe), 90
- His-fusion lysis buffer, pH 7.4 (recipe), 91
- His-fusion protein preparation from bacteria (protocol), 89–91
- Histograms, 736, 736f
- HLB (hydrophile-lipophile balance), 804
- HMT selection medium (recipe), 351
- Hock immunization  
injection into hock, 123–124  
of mice, rats, and hamsters (protocol), 168–169, 169f

- Hoechst dye 33258 staining  
properties of fluorochrome, 723t  
testing for mycoplasma contamination by, 332–333, 333f
- Hollow-fiber reactors, 314–316, 315f
- Homemade chemiluminescent substrate  
solution for HRP: solution A (recipe), 523
- Homemade chemiluminescent substrate  
solution for HRP: solution B (recipe), 524
- Homologous protein, designing peptides against, 53
- Horseradish peroxidase (HRP)  
in antibody capture assays, 210–211, 232, 242–245  
antibody conjugation to, 448, 450–451  
in antigen capture assays, 261–262  
in antigen detection on immunoblots, 519, 521–524  
detecting horseradish peroxidase–labeled cells  
using aminoethylcarbazole, 717  
using chloronaphthol, 716  
using diaminobenzidine, 713–714, 714f  
using diaminobenzidine and metal salts, 715
- Horses  
binding characteristics of Protein A, Protein G, and Protein L, 212t  
IgG binding affinity for Proteins A, G, and L, 540t
- Host cell protein (HCP) ELISA, 632, 655–656
- HPLC (high-pressure liquid chromatography), 373–374
- HPRT*. See Hypoxanthine-guanine phosphoribosyl transfer (*HPRT*) gene
- HRP*. See Horseradish peroxidase
- HT (hypoxanthine/thymidine) selection, 218, 224, 226
- Human hybridomas, 234–235
- Human isotype classes and associated Fc-binding proteins, 363t
- Humanization technology, 235
- Humans  
binding characteristics of Protein A, Protein G, and Protein L, 212t  
IgG binding affinity for Proteins A, G, and L, 540t  
isotype classes and associated Fc-binding proteins, 363t
- Hunter's TiterMax adjuvant, 114t, 115, 145
- HVJ (hemagglutinating virus of Japan), 221, 279–280
- Hybridoma(s). *See also* Monoclonal antibodies  
cell repositories, 309  
description of, 203  
feeding, 224  
growing (*see* Hybridomas, growing)  
history of development, 202, 203  
human, 234–235  
interspecies, 205, 234  
monoclonal antibody production by, 48  
production (*see* Hybridoma production)  
rescue strategy for nonviable hybridomas (protocol), 424–427  
materials, 424–425  
method, 425–427  
selecting best from fusion, 44
- Hybridoma Cloning Factor, 217, 224, 226–227, 269–270, 286–290
- Hybridoma cloning supplements, 217
- Hybridoma production  
chromosome loss, 205  
class-switching variants, selecting, 233–234  
cloning of hybridoma cells, 228  
contamination, dealing with, 229–231  
of a cloned line, 230–231  
common forms of contamination, 230f  
in fusion wells, 229–230  
expanding and freezing positive clones, 225–229, 227f  
single-cell cloning, 228  
unstable lines, 229
- feeding hybridomas, 224
- fusions, 220–222  
elimination of unfused cells by drug selection, 205, 206f  
overview of, 220–222  
polyethylene glycol as fusing agent, 205, 222  
Sendai virus use, 221
- future trends, 235–236  
antibody optimization, 235  
humanization technology, 235  
next generation mice, 236  
single-cell PCR technology, 235  
synthetic antibodies, 235–236
- human hybridomas, 234–235  
injection routes for, 120
- interspecies hybridomas, 234
- isotyping and subclassing of monoclonal antibodies, 231–234
- myeloma from BALB/c mice, 204–205  
overview of, 216–217  
plating strategies, 222–224  
bulk plating, 223  
multiple cells per well, 223, 223f  
single cell per well, 222–223, 222f  
soft agar use, 224, 224f
- preparation for fusions, 217–220  
drug selections, 218  
feeder layer plate preparation, 218  
final boost, 218–220  
hybridoma cloning supplements, 217  
low-density growth supplements, 217  
preparing myeloma cells for fusions, 219, 219f  
preparing partner cells for fusions, 218–219  
preparing splenocytes for fusions, 219, 219f–221f  
recombinant murine IL-6, 217
- progression of hybridoma growth postfusion, 226f
- screening method, 207–216, 225  
antibody capture assays, 209–213, 210f–211f, 212t, 213f  
antibody capture on nitrocellulose membrane: high-throughput  
western blot assay for hybridoma screening (protocol), 244–245  
antigen capture assays, 210f, 213–214  
characteristics of a good procedure, 207  
development of, 207–216  
examples of, 225  
functional assays, 215–216  
functional screens, 210f, 214–215  
for blocking/neutralizing or activating antibodies, 215  
for internalizing antibodies, 215, 216f  
for phospho-specific antibodies, 214–215  
pooling strategies, 225  
supernatant collection strategies for screening, 224–225  
timing of screening, 207  
stages of, 207, 208f–209f  
unstable, 205, 229
- Hybridomas, growing, 303–352  
cell culture, 304–309  
antibiotics for, 304, 306t  
long-term storage for, 309  
media, 304–307, 305t–306t  
sending and receiving hybridomas and myelomas, 309  
suppliers of media, 307t  
technique for, 307–308, 308f  
contamination of cell cultures, 309–313  
by bacteria, fungi, or yeast, 309–310  
by mycoplasma, 310–313, 311t–312t  
drug selection, 316–317  
checking cell lines for HGPRT deficiency, 316, 350–351  
selecting HGPRT mutants with 8-azaguanine, 316–317, 349
- monoclonal antibody production and storage, 313–316  
collecting tissue culture supernatants, 313–314  
comparison of methods, 313t  
hollow-fiber reactors, 314–316, 315f  
Integra CELLline 1000 flask, 314, 314f  
preparing tissue culture supernatants with higher concentrations of antibody, 314–316, 314f–315f  
roller bottles and large T-flasks, 314  
overview, 303–317  
protocols, 318–352  
ascites induction and collection, 344–345  
checking cell lines for HPRT deficiency, 350–352  
collecting tissue culture supernatants, 346  
counting myeloma or hybridoma cells, 318–319, 319f  
freezing cells for liquid nitrogen storage, 321–322  
recovering cells from liquid nitrogen storage, 323–324  
ridding cell lines of contaminating microorganisms by antibiotics, 325–326  
ridding cell lines of contaminating microorganisms by passage through mice, 328–329  
ridding cell lines of contaminating microorganisms with peritoneal macrophages, 327  
ridding cells of mycoplasma contamination by passage through mice, 342–343  
ridding cells of mycoplasma contamination using antibiotics and single-cell cloning, 340–341  
selecting myeloma cells for HGPRT mutants with 8-azaguanine, 349  
storing tissue culture supernatants and ascites, 347–348  
testing for mycoplasma contamination by growth on microbial media, 330–331, 331f

- testing for mycoplasma contamination by Hoechst dye 33258 staining, 332–333, 333f
- testing for mycoplasma contamination using PCR, 334–337, 335f
- testing for mycoplasma contamination using reporter cells, 338–339, 339f
- viability checks, 320
- Hydrazide, 432, 433t
- biotinylating antibodies using hydrazide-LC-biotin (protocol), 440–441
- Hydrazine, 377
- Hydrophile-lipophile balance (HLB), 804
- Hydrophilic amino acid exposure on protein surface, 52
- Hydrophilic peptides, advantages of, 52
- Hydroxyapatite chromatography, 374–375
- Hydroxylamine buffer (recipe), 447, 451
- Hydroxysuccinimide. *See N*-hydroxysuccinimide (NHS)
- HyperCyt, 738, 739t
- Hyperimmunization, 126–127
- Hypervariable regions, 14
- Hypoxanthine/aminopterin/thymidine (HAT) selection, 217, 218, 224, 267
- Hypoxanthine-guanine phosphoribosyl transfer (*HPRT*) gene, 205, 206f
- checking cell lines for *HPRT* deficiency, 316, 350–352
- selecting myeloma cells for *HGPRT* mutants with 8-azaguanine, 316–317, 349
- Hypoxanthine/thymidine (HT) selection, 218, 224, 226
- I**
- IDA (iminodiacetic acid), 375
- IgA. *See* Immunoglobulin A
- IgD. *See* Immunoglobulin D
- IgE. *See* Immunoglobulin E
- IgM. *See* Immunoglobulin M
- IgY. *See* Immunoglobulin Y
- IL-6, 34
- IMAC (immobilized metal affinity chromatography), 89–91
- Imaging, digital, 733
- IMDM medium, 305t–306t
- IMG-Abs platform mice, 236
- Iminodiacetic acid (IDA), 375
- 2-Iminoethanol (Traut's Reagent), 433
- Immobilized metal affinity chromatography (IMAC), 89–91, 375
- ImmunEasy adjuvant, 114t
- Immune complex. *See also* Antibody–antigen complex
- as antigens, 63–64
- conformational changes in, 23
- preparation for injection (protocol), 70–71
- stabilization by noncovalent bonds, 23
- Immune exhaustion, 6
- Immune response
- failure to induce, 46–47
- role in combating microbial invasion, 1–2
- weakened by gene knockout, 53
- Immune system
- antibody production by the, 1–7
- overview of, 1–7
- Immune tolerance, 6, 37–39
- Immunization. *See also* Immunization protocols; Immunizing animals
- cDNA, 61, 192–193, 193f
- decoy, 60, 190
- live cell preparation (protocol), 100
- subtractive, 60, 189
- transfected dendritic cell immunizations (protocol), 104–106
- Immunization protocols
- devising of, 131–132
- protocols, 182–193
- adoptive transfer immunization of mice, 191
- ascites induction in BALB/c mice using myeloma cells, 183
- ascites induction using Freund's adjuvant, 182
- cDNA immunization mice, rats, and hamsters, 192–193, 193f
- decoy immunization for mice, rats, and hamsters, 190
- repetitive immunization at multiple sites (RIMMS) of mice, rats, and hamsters, 188
- spleen harvesting from mice, rats, and hamsters, 196–197, 197f
- standard immunization of mice, rats, and hamsters, 184–185
- standard immunization of rabbits, 186–187
- subtractive immunization for mice, rats, and hamsters, 189
- selection of, 130–131, 131t
- Immunizing animals, 107–199
- adjuvants, 113–116
- advantages and disadvantages of specific, 114t
- aluminum hydroxide, 116
- Freund's, 114–115, 142–143, 143f
- GERBU, 116
- Hunter's TiterMax, 115, 145
- Magic Mouse, 115, 146–147
- overview of, 113–114
- Pam3Cys-Ser-(Lys)<sub>4</sub>, 115–116
- protocols, 142–149
- Ribi, 115, 144
- anesthesia, 112, 113t
- protocols, 136–141
- animal choice for, 109–110
- ascites fluid induction in mice, 129
- dose of antigen, 116–118
- for mice, 117t
- for rabbits, 117t
- for rats and hamsters, 118t
- exsanguination, 129
- form of immunogen, 118–119
- carbohydrates, 119
- insoluble, 118–119
- live cells, 119
- nucleic acids, 119
- recombinant proteins, 119
- soluble, 118
- synthetic peptides, 119
- immunization protocol
- devising of, 131–132
- protocols, 182–193
- selection of, 130–131, 131t
- legal and moral considerations of use, 108–109
- number of animals needed, 112
- overview, 108, 130
- polyclonal versus monoclonal antibodies, 109–110, 109t, 110t
- protocols, 136–199
- anesthesia and adjuvants, 136–149
- administering anesthesia to mice, rats, and hamsters, 136–138, 137f
- administering anesthesia to rabbits, 139–141
- aluminum hydroxide (alum) adjuvant preparation, 148–149
- Freund's adjuvant preparation, 142–143, 143f
- Hunter's TiterMax adjuvant use, 145
- Magic Mouse adjuvant use, 146–147
- Ribi adjuvant use, 144
- harvesting tissue, 194–199
- killing mice, rats, and hamsters using carbon dioxide asphyxiation, 194–195
- lymph node harvesting from mice, rats, and hamsters, 198–199, 199f
- spleen harvesting from mice, rats, and hamsters, 196–197, 197f
- immunization protocols, 182–193
- adoptive transfer immunization of mice, 191
- ascites induction in BALB/c mice using myeloma cells, 183
- ascites induction using Freund's adjuvant, 182
- cDNA immunization mice, rats, and hamsters, 192–193, 193f
- decoy immunization for mice, rats, and hamsters, 190
- repetitive immunization at multiple sites (RIMMS) of mice, rats, and hamsters, 188
- standard immunization of mice, rats, and hamsters, 184–185
- standard immunization of rabbits, 186–187
- subtractive immunization for mice, rats, and hamsters, 189
- routes of antigen injection, 150–169
- footpad or hock immunization of mice, rats, and hamsters, 168–169, 169f
- immunizing mice and rats with nitrocellulose-bound antigen, 154–156, 155f
- intradermal injection in rabbits, 159–160, 160f
- intramuscular injection in rabbits, 157–158, 158f
- intraperitoneal injection with adjuvant in mice and rats, 165, 165f
- intraperitoneal injection without adjuvant in mice and rats, 166–167, 166f–167f
- intravenous injection in mice, 163–164, 164f
- intravenous injection in rabbits, 161–162, 162f
- subcutaneous injection in rabbits, 150–151
- subcutaneous injection with adjuvant into mice and rats, 152
- subcutaneous injection without adjuvant into mice and rats, 153
- serum sampling and preparation, 170–181
- sampling mouse and rat serum from retro-orbital sinus, 175–176, 176f

- Immunizing animals, (*Continued*)
- sampling mouse and rat serum from saphenous vein, 179–180, 180f
  - sampling mouse and rat serum from submandibular vein, 177–178, 177f
  - sampling mouse serum from tail vein, 172–173, 173f
  - sampling rabbit serum from marginal ear vein, 170–171, 170f
  - sampling rat serum from tail vein, 174
  - serum preparation, 181
  - routes of injection, 120–127
    - affinity maturation and, 127
    - anaphylactic shock and, 122
    - boosts, 124
    - clonal dominance and, 127
    - decision on boost versus fusion, 126
    - genetic (naked DNA) immunization, 125
    - hyperimmunization and, 126–127
    - intradermal, 121–122, 159–160, 160f
    - intramuscular, 121, 157–158, 158f
    - intraperitoneal, 122–123, 165–167, 165f–167f
    - intravenous, 122, 161–164, 162f, 164f
    - into lymphoid organs, 123–124
    - for mice, rats, and hamsters, 120t
    - overview, 120
    - protocols, 150–169
    - for rabbits, 121t
    - repetitive immunization at multiple sites (RIMMS), 124, 125f, 125t
    - subcutaneous, 120–121, 150–153
  - sampling serum, 127–129, 128t, 170–181
  - sampling mouse and rat serum from retro-orbital sinus, 175–176, 176f
  - sampling mouse and rat serum from saphenous vein, 179–180, 180f
  - sampling mouse and rat serum from submandibular vein, 177–178, 177f
  - sampling mouse serum from tail vein, 172–173, 173f
  - sampling rabbit serum from marginal ear vein, 170–171, 170f
  - sampling rat serum from tail vein, 174
  - serum preparation, 129, 181
  - species/strain choice, 110–112, 110t, 111t
  - troubleshooting, 132–135
    - project 1, 132–133
    - project 2, 133
    - project 3, 133–134
    - project 4, 134
    - project 5, 134–135
- Immunoabsorbants, 539–541, 540t
- Immunoaffinity purification using anti-FLAG and anti-HA antibodies (protocol), 607–612
- discussion, 611
  - materials, 607–608
  - method: anti-FLAG purification, 607–608
  - method: anti-HA purification, 609–610
  - recipes, 612
  - troubleshooting, 610t–611t
- Immunoassays, 629–673
- antibody detection and quantification, 632
  - antigen detection and quantification, 630–631
  - bead-based ELISA, 642–643
  - blocking buffers, 635–636
  - BLOTTO, 635
  - bovine serum albumin (BSA)-based, 635
  - casein-based, 636
  - gelatin, 636
  - protein-free, 636
  - serum, 636
  - choosing a protocol, 631t
  - deciding where to start, 630
  - ELISA parameters, 639–640, 639f
  - ELISA validation parameters, 640–642, 640t
    - accuracy, 641
    - limit of detection, 641
    - linearity, 641
    - precision, 640
    - quantification limit, 641
    - range, 642
    - sensitivity, 641
    - specificity, 642
  - indirect versus direct detection, 632, 633f
  - microtiter plate selection, 632–635, 634f, 634t
  - overview, 629–643
  - protocols, 644–673
    - direct and indirect cell-based ELISA, 661–665, 663f–664f
    - direct competitive ELISA, 666–669, 666f
    - immunometric antibody sandwich ELISA, 651–657, 652f, 654t, 655f–656f
    - immunometric double-antibody sandwich ELISA, 658–660, 658f
    - immunometric indirect ELISA, 644–650, 644f–645f, 647t–649t
    - indirect competitive ELISA, 670–673, 671f, 673f
  - reporter-labeled secondary antibodies, 636–637, 637t
  - substrates, 637–639
    - chemifluorescent, 638–639
    - chemiluminescent, 638
    - chromogenic (colorimetric), 637–638
  - types, 642–643
  - wash buffers, 636
- Immunoblotting, 469–530
- antibody choice, 471–473, 472t
    - monoclonal antibodies, 472t, 473
    - polyclonal antibodies, 472–473, 472t
  - detection methods, 473, 474t
    - chromogenic, 477
    - enzymatic, 478
    - fluorochrome-labeled secondary reagents, 478
    - selection of, 477–478, 477f
    - signal amplification scale, 478
  - experimental strategies, 473–478
    - adjusting the primary and secondary antibody concentration, 476–477
    - blocking nonspecific binding sites on the membrane, 475–476, 476t
    - detection method selection, 477–478
    - immunoblotting of the immunoprecipitated proteins, 475, 476f
    - overview, 473–474
    - sample preparation, 474–475
  - optimizing primary antibody dilution for, 476f
  - overview, 470–478
  - protocols, 479–530
    - blocking and incubation with antibodies, 509–518
    - immunoblots prepared with immunoprecipitated protein antigens (immunoprecipitation/western blotting), 515–518
    - immunoblots prepared with whole-cell lysates and purified proteins (straight western blotting), 510–514
      - overview, 509
    - detection, 519–525
      - enzyme-based, 519, 521–524
      - with fluorochromes, 519–520, 525
    - reprobing membrane after immunoblotting, 526–530
      - overview, 526
      - stripping the blot for reprobing, 527–530
    - resolving proteins by gel electrophoresis, 490–496
      - materials, 491–492
      - method, 492–494
      - overview, 490
      - recipes, 495–496
      - troubleshooting, 494–495
    - sample preparation, 479–489
      - preparing immunoprecipitations for immunoblotting, 487–489
      - preparing protein solution for immunoblotting, 484–486
      - preparing whole-cell lysates for immunoblotting, 480–483
      - transfer of proteins from gels to membranes, 497–508
        - overview, 497
        - semi-dry electrophoretic transfer, 499–502, 500f
        - staining the blot for total protein with Ponceau S, 507–508
        - wet electrophoretic transfer, 503–506
    - schematic of classical procedure, 470f
    - steps in, 471
    - strength of antibody binding, 25t
- ImmunoCruz series, 509
- Immunodepletion of serum, 379–381, 379f–380f, 382f
- Immunodiffusion. *See* Ouchterlony double-diffusion assays
- Immunofluorescence
- antibody capture on permeabilized whole cells, 253–254
  - surface staining by, 251–252
- Immunogen(s). *See also* Antigen(s)
- accumulation in lymphoid organ, 4
  - chemical features of, 46, 46t
  - coupling antigens, 50t, 62–64
  - defined, 2
  - form for immunizing animals, 118–119
    - carbohydrates, 117t, 118t, 119
    - dose of antigen, 116–118, 117t, 118t
    - insoluble proteins, 117t, 118–119, 118t
    - live cells, 117t, 118t, 119
    - nucleic acids, 117t, 118t, 119
    - particulate proteins, 117t, 118t
    - recombinant proteins, 119
    - soluble proteins, 117t, 118, 118t
    - synthetic peptides, 119
  - properties of good, 45–46, 46t
  - size limit, 45, 53
  - sources of, 49–61, 49t
    - cDNA, 49t, 61
    - cell and tissue lysates, 49t, 59–60
    - haptens, 50
    - purified native proteins, 49t, 54–55
    - recombinant proteins, 49t, 55–59
    - synthetic peptides, 49t, 50–54
- ImmunoGenes, 236

- Immunogenicity, 44–49  
 antigen valency affect on, 119  
 defined, 2, 44  
 failure of animal to respond, 46–47  
 polyclonal versus monoclonal antibodies, 47–48, 47t  
 properties of good immunogens, 45–46, 46t  
 of pure antigens (purified native proteins), 54  
 selecting the antigen and, 48, 49t  
 strengthening, 61–64  
 synthetic class II–T-cell receptor sites, 47t
- Immunoglobulin(s). *See also* Antibody class-switching, 18f, 19, 39, 233–234  
 defined, 2  
 structures of, 232f
- Immunoglobulin A (IgA)  
 characteristics of, 13t  
 Fc-binding proteins, 363t  
 function, 362  
 structure, 12, 232f, 362  
 subclasses, 10
- Immunoglobulin D (IgD)  
 characteristics of, 13t  
 function, 362  
 structure, 232f
- Immunoglobulin E (IgE)  
 characteristics of, 13t  
 Fc-binding proteins, 363t  
 function, 362, 364  
 structure, 232f
- Immunoglobulin G (IgG)  
 affinity for antigen, 39  
 anion-exchange chromatography, 373–374  
 binding affinity for proteins A, G, and L, 539–540, 540t  
 characteristics of, 13t  
 chicken, 376  
 class-switching, 233–234  
 cross-linking antibodies to beads, 591–592  
 Fc-binding proteins, 363t  
 functions of, 362, 364  
 high-pH DEAE chromatography (protocol), 391–392  
 in hyperimmune sera, 126–127  
 isolation of a total IgG fraction, 372–373  
 ammonium sulfate precipitation (protocol), 372–373, 385–386  
 caprylic acid IgG isolation (protocol), 373, 387–388  
 isotyping, 361–362  
 low-pH DEAE chromatography (protocol), 389–390  
 Protein A purification, 393–394  
 Protein G purification, 395–396  
 purification of Fab and F(ab')<sub>2</sub> fragments, 376  
 secondary response and, 33  
 structure, 10–11, 12–13, 232f  
 subclasses, 10
- Immunoglobulin M (IgM)  
 affinity for antigen, 39  
 characteristics of, 13t  
 class-switching, 233–234  
 Fc-binding proteins, 363t  
 function, 362, 364  
 primary response and, 32  
 purification, 376–377  
 structure, 11–13, 232f
- Immunoglobulin Y (IgY)  
 described, 375–376  
 isolation of IgY from chicken eggs:  
 polyethylene glycol method (protocol), 399–400  
 isolation of IgY from chicken eggs: sodium sulfate method (protocol), 397–398
- Immunohistochemistry  
 antibody capture on tissue sections (protocol), 255–257
- Immunological memory, 4, 6
- Immunometric antibody sandwich ELISA, 651–657, 652f, 654t, 655f–656f
- Immunometric double-antibody sandwich ELISA, 658–660, 658f
- Immunometric indirect ELISA, 644–650, 644f–645f, 647t–649t
- Immunoprecipitated proteins  
 immunoblotting of, 475  
 blocking and incubation with antibodies: (protocol), 515–518  
 preparing for immunoblotting (protocol), 487–489  
 visualizing, 541–542
- Immunoprecipitation, 531–627  
 antibodies  
 monoclonal, 538  
 polyclonal, 537–538  
 antigen–antibody complex formation, 538  
 antigen capture assay, 214  
 antigen capture in solution (protocol), 263  
 background problems  
 nonspecific background, 543, 604t  
 specific background, 543, 604t  
 cell lysis  
 denaturing lysis (protocol), 588–590  
 detergent lysis of animal tissues (protocol), 568–570  
 detergent lysis of tissue culture cells (protocol), 565–567  
 differential detergent lysis of cellular fractions (protocol), 575–578  
 freezing cell pellets for large-scale immunoprecipitation (protocol), 563–564  
 lysing yeast cells using a coffee grinder (protocol), 585–587  
 lysing yeast cells with glass beads (protocol), 579–581  
 using lysis buffer 2 without detergents (protocol), 582–584  
 lysis using dounce homogenization (protocol), 571–574  
 overview, 534–537  
 lysis buffers, 534–535  
 lysis of tissue, 536–537  
 lysis of tissue culture cells, 535–536  
 lysis of yeast, 537  
 protease inhibitor use, 535, 536t  
 protocols, 565–590  
 cell preparation, 534  
 chromatin (ChIP)  
 dual cross-linking for (protocol), 625–627  
 overview, 614  
 protocol, 617–624  
 blocking and antibody coating of magnetic beads, 620  
 chromatin preparation, 619  
 chromatin quality and quantity determination and input  
 chromatin preparation, 619  
 cross-linking of DNA and protein, 618  
 discussion, 621–622  
 DNA purification, amplification, and sequencing, 621  
 elution, 620  
 materials, 617–618  
 method, 618–621  
 recipes, 622–624  
 reverse cross-linking, 621  
 setting up the ChIP, 620  
 troubleshooting, 621t  
 washing, 620
- coimmunoprecipitation, 532  
 controls, 543–544  
 cross-linking antibodies to beads  
 overview, 541, 591–592, 592f  
 using dimethyl pimelimidate (DMP), 591, 592f, 593–596  
 using disuccinimidyl subpimelimidate (DSS), 591, 592f, 597–600
- epitope tags, 539  
 experimental strategies, 533f  
 immunoadsorbants, 539–541, 540t  
 magnetic beads, 793  
 optimization, 542–543  
 overview, 532–534, 533f  
 phases of technique, 532, 533f  
 protocol for, 602–606  
 discussion, 605  
 materials, 602  
 methods, 602–603  
 recipes, 606  
 troubleshooting, 604t–605t
- radiolabeling of protein antigens  
 metabolic labeling of antigens with [<sup>32</sup>P] orthophosphate (protocol), 558–562  
 discussion, 561  
 materials, 558–559  
 method, 559–561  
 for monolayer-cultured cells, 559–560  
 recipes, 561–562  
 for suspension-cultured cells, 560–561  
 metabolic labeling of antigens with [<sup>35</sup>S] methionine (protocol), 546–551  
 discussion, 549–550  
 materials, 546–547  
 method, 547–549  
 recipes, 550–551  
 suggested labeling amounts, 547t  
 troubleshooting, 549  
 overview, 534, 545  
 pulse-chase labeling of antigens with [<sup>35</sup>S] methionine (protocol), 552–557  
 discussion, 555–556  
 materials, 552–553  
 method, 553–555  
 monolayer-cultured cells, 554  
 recipes, 556–557  
 suspension-cultured cells, 554–555  
 radioisotopes used in metabolic labeling, 559t  
 strength of antibody binding, 25t  
 tandem immunofluorescence purification using anti-FLAG and anti-HA antibodies (protocol), 607–612  
 discussion, 611  
 materials, 607–608  
 method: anti-FLAG purification, 607–608  
 method: anti-HA purification, 609–610  
 recipes, 612  
 troubleshooting, 610t–611t  
 visualizing immunoprecipitated proteins, 541–542

- Inclusion bodies, 56  
sarkosyl preparation of antigens from bacterial inclusion bodies (protocol), 95–96
- Inclusion body lysis buffer (recipe), 96
- Incomplete Freund's adjuvant, 114
- India ink, 81, 497
- Indirect ELISA  
advantages and disadvantages, 633f  
antibody capture assay, 211f  
antibody capture in polyvinyl chloride wells (protocols)  
enzyme-linked detection, 238–239  
enzyme-linked detection when immunogen is an immunoglobulin fusion protein, 240–241  
cell-based ELISA, 661–665, 663f–664f  
competitive, 670–673, 671f, 673f  
direct versus, 632, 633f  
immunometric, 644–650, 644f–645f, 647t–649t
- Influenza hemagglutinin, 10f
- Injection routes, 120–127  
anaphylactic shock and, 122  
boosts, 124  
footpad, 123, 168–169, 169f  
genetic (naked DNA) immunization, 125  
hock, 123–124, 168–169, 169f  
intradermal, 121–122, 159–160, 160f  
intramuscular, 121, 157–158, 158f  
intraperitoneal, 122–123, 165–167, 165f–167f  
intravenous, 122, 161–164, 162f, 164f  
into lymphoid organs, 123–124  
for mice, rats, and hamsters, 120t  
overview, 120  
protocols, 150–169  
footpad or hock immunization of mice, rats, and hamsters, 168–169, 169f  
immunizing mice and rats with nitrocellulose-bound antigen, 154–156, 155f  
intradermal injection in rabbits, 159–160, 160f  
intramuscular injection in rabbits, 157–158, 158f  
intraperitoneal injection with adjuvant in mice and rats, 165, 165f  
intraperitoneal injection without adjuvant in mice and rats, 166–167, 166f–167f  
intravenous injection in mice, 163–164, 164f  
intravenous injection in rabbits, 161–162, 162f  
subcutaneous injection in rabbits, 150–151  
subcutaneous injection with adjuvant into mice and rats, 152  
subcutaneous injection without adjuvant into mice and rats, 153  
for rabbits, 121t  
repetitive immunization at multiple sites (RIMMS), 124, 125f, 125t  
subcutaneous, 120–121, 150–153
- Innate immunity  
described, 1  
link to adaptive immunity, 2–3
- Insect. *See also* Baculovirus  
cells, 58, 58t
- Insoluble proteins as immunogen form for immunizing animals, 117t, 118–119, 118t
- Institutional safety office, 819
- Integra CELLline 1000 flask, 314, 314f
- Intensifying screens, 775
- Interleukin-6 (IL-6), 34
- Intermolecular bridges, 25, 26f
- Internalizing antibodies, screening for, 215, 216f
- Interspecies hybridomas, 205, 234
- Intracellular staining by flow cytometry/FACS, 249–250
- Intradermal injection, 121–122  
in rabbits (protocol), 159–160, 160f
- Intramuscular injection, 121  
in rabbits (protocol), 157–158, 158f
- Intraperitoneal injection, 122–123  
with adjuvant in mice and rats (protocol), 165, 165f  
without adjuvant in mice and rats (protocol), 166–167, 166f–167f
- Intravenous injection, 122  
in mice (protocol), 163–164, 164f  
in rabbits (protocol), 161–162, 162f
- InvivoGen Plasmotest Kit, 338–339, 339f
- Iodine  
detecting iodine-labeled reagents, 727–728  
iodination of antibodies with immobilized iodogen (protocol), 462–463
- Iodoacetyl, in conjugation of peptides to thiol-reactive gel protocol, 401–402
- Ion-exchange chromatography, for cleanup and purification of antibody conjugates, 464–465
- Ion-exchange methods, 374–375
- Ionic detergents, 535, 805, 806t
- IP. *See* Immunoprecipitation
- Isoelectric focusing  
two-dimensional isoelectric focusing/  
SDS-polyacrylamide gel electrophoresis, 762–764
- Isoflurane, 112, 113t, 136–137, 136f, 140
- Isothermal calorimetry (ITC), 361
- Isotype  
described, 361  
human isotype classes and associated Fc-binding proteins, 363t  
isotyping, 361–362, 366–370
- Isotype determination of rodent-derived monoclonal antibodies using sandwich ELISA (protocol), 366–370  
materials, 366–367  
method, 367–369  
binding anti-light-chain detection antibodies, 369  
blocking the wells, 367  
capturing sample and positive control antibodies, 369  
coating ELISA plate with capture antibody, 367  
color development, 369  
plate layouts, 368f  
preparing anti-light-chain detection antibodies, 369  
sample preparation, 367  
recipe, 370  
troubleshooting, 370
- ITC (isothermal calorimetry), 361
- K**
- $\kappa$  gene, DNA rearrangement and, 14–15, 15f
- Ketamine/diazepam for anesthesia, 140
- Ketamine/xylazine for anesthesia, 113t
- Keyhole limpet hemocyanin (KLH)  
choosing as carrier, 54  
coupling antigens to, 62  
coupling haptens to, 50  
cross-linking peptides to KLH with maleimide (protocol), 85–86
- KLH buffer (recipe), 86
- Knockout mice, for antibodies against highly homologous protein, 53
- Kunkel mutagenesis, 422
- Kymab, 236
- Kymouse, 236
- Kyte-Doolittle hydrophobicity program, 51
- L**
- Labeling antibody  
cleanup and purification of antibody conjugates, 464–468  
affinity chromatography, 465  
desalting or buffer exchange using size-exclusion chromatography (protocol), 467–468  
dialysis, 465–466  
ion-exchange chromatography, 464–465  
overview, 464–466, 464t  
reversed-phase chromatography, 465  
size-exclusion chromatography, 464, 464t, 467–468  
cross-linker selection, 431–433, 432t, 433t  
amines/carbonyls, 431–432, 432t, 433t  
carbohydrates (aldehydes), 432, 433t  
sulfhydryls, 432t, 433, 433t  
labeling by biotinylation, 435–441  
labeling using biotin polyethylene oxide (PEO) iodoacetamide (protocol), 438–439  
labeling using hydrazide-LC-biotin (protocol), 440–441  
labeling with NHS-LC-Biotin (protocol), 436–437  
overview, 435  
labeling with fluorophores, 442–447  
labeling using a maleimido dye (protocol), 446–447  
labeling using NHS-fluorescein (protocol), 444–445  
list of fluorophores, 442t  
overview, 442–443, 442t  
labeling with metals and elements, 455–460  
labeling with colloidal gold (protocol), 459–460  
labeling with europium (protocol), 457–458  
overview, 455–456  
overview, 429–430, 430f  
protein–antibody conjugate formation, 448–454  
conjugation to horseradish peroxidase (HRP) (protocol), 450–451  
labeling with Cy5-phycoerythrin (protocol), 452–454  
overview, 448–449  
protocols, 435–468  
radiolabeling, 461–463  
autoradiography protocol, 83–84  
iodination with immobilized iodogen (protocol), 462–463  
overview, 461  
SDS-PAGE gel and, 55  
storage of antibody conjugates, 466  
target choice, 430–431

- Label medium (recipe), 550, 556, 562  
*Lactobacillus bulgaricus*, 116  
 Laemmli sample buffer, 474–475  
 Laemmli sample buffer (2×) (recipe), 606, 612  
 λ gene, DNA rearrangements, 15, 16f  
 λgt11, 812f  
 λ repressor, affinity of, 24  
 Large-scale antibody production, 382–383  
 Lentivirus expression vector, 104–105  
 Light chain, 10, 12, 12f–13f, 14  
 Limit of detection (LoD), ELISA, 641  
 Limit of linearity (LoL), ELISA, 640  
 Lincomycin, addition to culture medium, 340–341  
 Linearity, ELISA, 641  
 Lipid A, 113  
 Lipopolysaccharide (LPS), 113  
 Liposomes, 113  
 Liquid nitrogen storage  
   freezing cells for, 321–322  
   recovering cells from, 323–324  
 Liquids, concentrations of commercial, 803t  
 Live cells  
   immunogen form for immunizing animals, 117t, 118t, 119  
   preparation for immunization (protocol), 100  
 LoD (limit of detection), ELISA, 641  
 Log-odds matrix for relationships between protein sequences, 785t  
 LoL (limit of linearity), ELISA, 640  
 Low-density growth supplements, 217  
 Lowry protein quantification, 792  
 LPS (lipopolysaccharide), 113  
 Lymph node  
   harvesting, 220f  
   harvesting from mice, rats, and hamsters (protocol), 198–199, 199f  
   injection into, 123  
   purification of B cells by negative selection, 282  
 Lymphoid organs, injection into, 123–124  
 Lymphokines, 113  
 Lyophilization  
   for antibody storage, 383–384  
   of gel slice (protocol), 78  
 Lysine. *See* Poly-L-lysine  
 Lysing yeast (protocol), 708  
 Lysis. *See* Cell lysis  
 Lysis buffers, 534–535  
   recipes  
     lysis buffer 1 (1×), 583, 587  
     lysis buffer 2 (1×), 583  
     lysis buffer 1 containing protease inhibitors, 583  
     lysis buffer 1 for ChIP, 623  
     lysis buffer 2 for ChIP, 623  
     lysis buffer 3 for ChIP, 623  
 Lysozyme, epitope of, 22  
 Lysozyme–antibody complex, 22–23
- M**
- Macrophages, 33–34  
   peritoneal macrophage feeder plate preparation, 266  
   ridding cell lines of contaminating microorganisms with peritoneal macrophages, 327  
   ridding cells of mycoplasma contamination using antibiotics and single-cell cloning (protocol), 340–341
- Magic Mouse adjuvant, 115, 146–147  
 Magnetic beads-immunoprecipitation, 540–541, 793  
 Major histocompatibility complex (MHC), 2, 2f  
 Major histocompatibility complex (MHC) class II protein, 34–36, 45  
   alleles for, 111, 111t  
   failure to bind antigen fragments, 47  
 Major histocompatibility complex (MHC) class II-T-cell receptor binding site  
   coupling antigens and, 62–63  
   synthetic, 45, 47, 47t  
 Major histocompatibility complex (MHC) class II-T-cell receptor sites, 63  
 Maleimide, 433, 433t  
   in conjugation of peptides to thiol-reactive gel (protocol), 401–402  
   cross-linking peptides to KLH with maleimide (protocol), 85–86  
   horseradish peroxidase and, 451  
   labeling antibodies using a maleimido dye (protocol), 446–447  
 Maleimide linkage, 54  
 Maltose-binding protein (MBP), 55, 56t  
   as affinity tag, 539  
   MBP-fusion protein preparation from bacteria (protocol), 92–94  
 Mammalian cells  
   mFc- and hFc-fusion protein preparation (protocol), 97–99  
   for recombinant protein expression, 56–57, 57t, 58t  
 Mammalian overexpression vectors, preparing antigens from, 56–57, 57t
- Maps  
   bacterial expression and  
     β-gal fusion vectors, 815f  
     gateway expression vectors, 817f  
     λgt11, 812f  
     pcDNA 3.1, 816f  
     pDEST 8, 818f  
     pDEST 15, 817f  
     pDEST 27, 817f  
     pET-SUMO, 816f  
     pFastBac1, 816f  
     plasmids, 813f–818f  
     Trp fusion vectors, 814f  
     T7 vectors, 813f  
   partial proteolytic peptide maps, 760–761  
 Marginal ear vein, sampling rabbit serum from (protocol), 170–171, 170f  
 Material safety data sheets (MSDSs), 819  
 Matrigel, embedding cultured cells in (protocol), 701–702  
 MBP. *See* Maltose-binding protein  
 MBP binding buffer (recipe), 93  
 MBP elution buffer (recipe), 93  
 MBP-fusion protein preparation from bacteria (protocol), 92–94  
 MBP lysis buffer (recipe), 94  
 MDP (muramyl dipeptide), 113  
 Medical Pathological Waste (MPW), 821  
 MegAlign program, 51  
 Membranes, transfer of proteins from gels to, 497–508  
   overview, 497  
   semi-dry electrophoretic transfer (protocol), 499–502, 500f  
   staining the blot for total protein with Ponceau S (protocol), 507–508  
   wet electrophoretic transfer (protocol), 503–506
- Memory B cells, 3, 3f, 4, 32–33, 39–40, 40f  
   secondary response and, 32, 33  
 Memory T cells, 33  
 Metabolic labeling  
   of antigens with [<sup>32</sup>P] orthophosphate (protocol), 558–562  
     discussion, 561  
     materials, 558–559  
     method, 559–561  
     for monolayer-cultured cells, 559–560  
     recipes, 561–562  
     for suspension-cultured cells, 560–561  
   of antigens with [<sup>35</sup>S] methionine (protocol), 546–551  
     discussion, 549–550  
     materials, 546–547  
     method, 547–549  
     recipes, 550–551  
     suggested labeling amounts, 547t  
     troubleshooting, 549  
   radioisotopes used in, 559t  
 Metal salts, detecting horseradish peroxidase-labeled cells using diaminobenzidine and (protocol), 715  
 Metals and elements, labeling antibodies with, 455–460  
   labeling with colloidal gold (protocol), 459–460  
   labeling with europium (protocol), 457–458  
   overview, 455–456  
   colloidal gold, 455  
   heavy metal chelators, 455  
   quantum dots, 455–456  
 Methionine  
   metabolic labeling of antigens with [<sup>35</sup>S] methionine (protocol), 546–551  
   pulse-chase labeling of antigens with [<sup>35</sup>S] methionine (protocol), 552–557  
 Methotrexate, 205, 218, 316  
 Metoclopramide, 141  
 mFc- and hFc-fusion protein preparation from mammalian cells (protocol), 97–99  
 mFc IgG2a receptor, 57  
 MHC. *See* Major histocompatibility complex  
 Mice  
   administering anesthesia to (protocol), 136–138, 137f  
   adoptive transfer immunization of mice (protocol), 191  
   age of immune maturation, 112  
   antigen dose for, 116, 117t  
   ascites induction, 129  
     in BALB/c mice using myeloma cells (protocol), 183  
   binding characteristics of Protein A, Protein G, and Protein L, 212t  
   bleed sample amount from, 110  
   boost injections in, 124  
   cDNA immunization (protocol), 192–193, 193f  
   cell lines used for myeloma induction, 204–205, 204t  
   choice of species for producing antibodies, 110, 111–112  
   decoy immunization for (protocol), 190  
   footpad or hock immunization (protocol), 168–169, 169f  
   haplotypes, 111t  
   IgG binding affinity for Proteins A, G, and L, 539–540, 540t

- Mice (*Continued*)
- immunizing with nitrocellulose bound antigen (protocol), 154–156, 155f
  - injection routes for, 120, 120t
  - injection volume for, 121
  - intraperitoneal injection
    - with adjuvant in (protocol), 165, 165f
    - without adjuvant in (protocol), 166–167, 166f–167f
  - intravenous injection in (protocol), 163–164, 164f
  - killing using carbon dioxide asphyxiation (protocol), 194–195
  - lymph node harvesting from (protocol), 198–199, 199f
  - next generation, 236
  - repetitive immunization at multiple sites (RIMMS) (protocol), 188
  - ridging cell lines of contaminating microorganisms by passage through mice (protocol), 328–329
  - ridging cells of mycoplasma contamination by passage through mice (protocol), 342–343
  - serum sampling protocols
    - from retro-orbital sinus, 175–176, 176f
    - from saphenous vein, 179–180, 180f
    - from submandibular vein, 177–178, 177f
    - from tail vein, 172–173, 173f
  - spleen harvesting from (protocol), 196–197, 197f
  - standard immunization (protocol), 184–185
  - strains of laboratory, 803t
  - subcutaneous injection
    - with adjuvant into (protocol), 152
    - without adjuvant into (protocol), 153
  - subtractive immunization (protocol), 189
  - test bleeds in, 128–129
- Micelle molecular weight, 804
- Microbial invasion, immune response to, 1–2
- Microorganisms, contamination of cell cultures by, 230f, 309–310
- overview, 309–310
  - ridging cell lines of contaminating microorganisms
    - by antibiotics (protocol), 325–326
    - by passage through mice (protocol), 328–329
    - with peritoneal macrophages (protocol), 327
- Microtiter plate
- selection for ELISA, 632–635
  - surface properties, 634t
  - well shape and dimensions, 634f
- Microwave safety, 820
- Mineral oil in myeloma induction, 204
- Mitochondrial genetic code, 782t
- Mobility of amino acid residues, 52
- Modifying antigens. *See* Antigen modification
- Molecular weight standards, 779t
- Monkeys
- IgG binding affinity for Proteins A, G, and L, 540t
- Monoclonal antibodies. *See also* Hybridoma(s)
- affinity of, 24
  - binding to multimeric antigen, 25
  - for cell staining, 677t, 678
  - choosing versus polyclonal, 109, 110t, 203t, 354
  - class-switching variants, selecting, 233–234
  - decision to boost again or fuse, 126
  - history of development, 202
  - immunoblotting, 472t, 473
  - immunochemical techniques using, 203t
  - immunological techniques, 47t
  - for immunoprecipitation, 538
  - isotyping and subclassing of, 231–234, 361, 366–370
    - Cytometric Bead Assay (CBA), 232
    - ELISA assays, 232
    - Ouchterlony double-diffusion assay, 231–232
  - polyclonal antibody versus, 47, 48
  - producing (*see* Monoclonal antibody generation)
  - properties of, 109–110, 109t
  - specificity of, 48, 353–354
  - usefulness of, 203, 203t
- Monoclonal antibody generation
- comparison of production methods, 313t
  - hybridomas (*see* Hybridoma production) protocols, 238–301
    - antibody capture in polyvinyl chloride wells
      - enzyme-linked detection (indirect ELISA), 238–239
      - enzyme-linked detection when immunogen is an immunoglobulin fusion protein (indirect ELISA to detect Ig fusion proteins), 240–241
    - antibody capture on nitrocellulose membrane
      - dot blot, 242–243
      - high-throughput western blot assay for hybridoma screening, 244–245
    - antibody capture on permeabilized whole cells
      - immunofluorescence, 253–254
      - intracellular staining by flow cytometry/FACS, 249–250
    - antibody capture on tissue sections (immunohistochemistry), 255–257
    - antibody capture on whole cells
      - cell-surface binding (surface staining by flow cytometry/FACS), 246–248
      - cell-surface binding (surface staining by immunofluorescence), 251–252
    - antigen capture in solution:
      - immunoprecipitation, 263
    - antigen capture in 96-well plates (capture or sandwich ELISA), 258–260
    - antigen capture on nitrocellulose membrane: reverse dot blot, 261–262
    - determining the class and subclass of a monoclonal antibody
      - by ouchterlony double-diffusion assays, 291–293, 292f
      - using antibody capture on antigen-coated plates, 294–296, 295f
      - using antibody capture on anti-immunoglobulin antibody-coated plates, 297–299
      - using flow cytometry, 300–301
    - electro cell fusion, 281–285, 282f
    - fibroblast feeder cell culture preparation, 271
    - fusion by sendai virus, 279–280
    - myeloma cell feeder plate preparation, 267–268
    - peritoneal macrophage feeder plate preparation, 266
    - polyethylene glycol fusion, 274–278
    - screening for good batches of fetal bovine serum, 264–265
    - screening for good batches of polyethylene glycol, 272–273
    - single-cell cloning by growth in soft agar, 288–290
    - single-cell cloning by limiting dilution, 286–287
    - splenocyte feeder cell culture preparation, 269–270
  - MOPC (mineral oil plasmacytoma), 204
  - Mounting cell or tissue samples (protocols) in DPX, 730
    - in Gelvatol or Mowiol, 731
  - Mouse antibody production, 60
  - Mowiol, mounting cell or tissue samples in (protocol), 731
  - MPW (Medical Pathological Waste), 821
  - MRC-5 fibroblasts, 271
  - MSDSs (material safety data sheets), 819
  - Multiplexing, flow cytometry and, 737, 740
  - Muramyl dipeptide (MDP), 113
  - Murine IL-6, recombinant, 217
  - Mutagenesis
    - for epitope mapping, 355–356
    - Kunkel, 422
    - modification of antibody function by (protocol), 422–423
    - materials, 422
    - method, 423
  - Mycobacterium tuberculosis*, 62, 113, 114, 142
  - Mycoplasma* contamination of cell cultures, 310–313, 311t–312t
    - colony appearance on agar plates, 330–331, 331f
    - detecting, 310–312, 311t, 330–339
    - effects on cultured cells, 310, 311t
    - eliminating, 312–313, 340–343
    - protocols
      - ridging cells of mycoplasma contamination by passage through mice, 342–343
      - ridging cells of mycoplasma contamination using antibiotics and single-cell cloning, 340–341
      - testing for mycoplasma contamination by growth on microbial media, 330–331, 331f
        - agar plate method, 330–331
        - broth culture method, 331
      - testing for mycoplasma contamination by Hoechst dye 33258 staining, 332–333, 333f
      - testing for mycoplasma contamination using PCR, 334–337, 335f
      - testing for mycoplasma contamination using reporter cells, 338–339, 339f
    - resistance to antibiotics, 312, 312t, 313
    - sources of contamination, 310, 312t
  - Myeloma. *See also* Hybridomas
    - ascites induction in BALB/c mice using myeloma cells (protocol), 183
    - from BALB/c mice, 204–205
    - cell feeder plate preparation (protocol), 267–268
    - cell line family tree, 204f



- cell lines used as fusion parents, 204t  
cell repositories, 309  
fusion of cells  
  elimination of unfused cells by drug selection, 205, 206f  
  polyethylene glycol as fusing agent, 205  
  preparing cells for fusions, 219, 219f  
fusion protocols  
  electro cell fusion, 281–285  
  fusion by Sendai virus, 279–280  
  polyethylene glycol fusion, 274–278  
growing  
  cell culture, 304–309  
    antibiotics for, 304, 306t  
    long-term storage for, 309  
    media, 304–307, 305t–306t  
    sending and receiving myelomas, 309  
    suppliers of media, 307t  
    technique for, 307–308  
  contamination of cell cultures, 309–313  
    by bacteria, fungi, or yeast, 309–310  
    by mycoplasma, 309–313, 311t–312t  
  counting myeloma cells (protocol), 318–319, 319f  
  protocols, 318–352  
  selecting myeloma cells for HGPRT mutants with 8-azaguanine (protocol), 349
- N**
- NABP-NF, detecting alkaline phosphatase-labeled cells (protocol), 718  
NanoDrop protein quantification, 793  
Nanoparticles, gold, 455, 459–460  
Naphthol-AS-BI-phosphate (NABP)/New Fuchsin, detecting alkaline phosphatase-labeled cells (protocol), 718  
National Institute of Environmental Health and Human Services, 823  
Native proteins, 49t, 54–55  
Natural killer cells, ADCC and, 751  
NBT stock solution for AP (recipe), 524  
Neo-antigenic, 57  
Neonatal Fc receptor (FcRn), 236  
Neuraminidase, epitope of, 22  
Neuraminidase–antibody complex, 22–23  
NHS. *See* N-hydroxysuccinimide  
N-hydroxysuccinimide (NHS), 377, 431–432  
  cross-linking antibodies to beads and, 591, 592f, 597  
  labeling antibodies using NHS-fluorescein (protocol), 444–445  
  labeling antibodies with NHS-LC-Biotin (protocol), 436–437  
96-well plates  
  antigen capture in (capture or sandwich ELISA), 258–260  
  described, 633–634  
  hybridoma plating strategies  
    multiple cells per well, 223, 223f  
    single cell per well, 222–223, 222f  
  staining cells for flow cytometry in, 247–248  
Nitrotriacetic acid (NTA), 375  
Nitro blue tetrazolium/bromochloroindolyl (NBT/BCIP) substrate for horseradish peroxidase, 519, 522  
Nitrocellulose  
  adjuvant, 114t  
  antibody capture on nitrocellulose membrane dot blot, 242–243  
  high-throughput western blot assay for hybridoma screening, 244–245  
  antigen capture on nitrocellulose membrane:  
    reverse dot blot (protocol), 261–262  
  blocking and incubation of immunoblots with antibodies, 509–518  
  immunoblots prepared with immunoprecipitated protein antigens (immunoprecipitation/western blotting), 515–518  
  immunoblots prepared with whole-cell lysates and purified proteins (straight western blotting), 510–514  
  electrophoretic transfer to membranes (protocol), 81–82  
  immunizing mice and rats with nitrocellulose-bound antigen (protocol), 154–156, 155f  
  immunoblotting, 470  
  staining immunoblot for total protein with Ponceau S (protocol), 507–508  
  transfer of proteins from gels to membranes, 497–508  
    overview, 497  
    semi-dry electrophoretic transfer (protocol), 499–502, 500f  
    staining the blot for total protein with Ponceau S (protocol), 507–508  
    wet electrophoretic transfer (protocol), 503–506  
  Noncovalent interactions, in antibody–antigen complex, 23  
  Non-fat dried milk, as blocking solution, 509  
  Nonidet P-40, 535  
  Nonidet P-40 lysis buffer (recipe), 567  
  Nonionic detergents, 535, 805, 806f  
  NOTA (1,4,7-triazacyclononane-*N,N',N''*-triacetic acid), 455  
  *N*-succinimidyl *S*-acetylthioacetate (SATA), 433  
  in antibody conjugation to horseradish peroxidase protocol, 450–451  
  labeling antibodies using a maleimido dye (protocol), 446–447  
  NTA (nitrotriacetic acid), 375  
  Nucleic acids, as immunogen form for immunizing animals, 117t, 118t, 119  
  Nystatin, 325
- O**
- Occupational Safety and Health Administration (OSHA), 819  
Oligonucleotides, creation of recombinant antibodies using degenerate oligonucleotides (protocol), 407–409  
  discussion, 408–409  
  materials, 407–408  
  method, 408  
Oncogenes, 235  
OPI (oxaloacetate pyruvate insulin), 217, 226, 269–270, 286–290  
OPI supplement (recipe), 270, 285, 287, 290  
Optical biosensor methods for measurement of antibody affinity, 360–361  
Organic solvents, fixing attached cells in, 703–704  
Orthophosphate  
  metabolic labeling of antigens with [<sup>32</sup>P] orthophosphate (protocol), 558–562  
OSHA (Occupational Safety and Health Administration), 819  
Ouchterlony double-diffusion assays, 231–232  
  determining the class and subclass of a monoclonal antibody (protocol), 291–293, 292f  
  precipitin line, 232, 292f  
Ovalbumin (OVA)  
  coupling antigens to, 62  
  coupling haptens to, 50  
Oxaloacetate pyruvate insulin (OPI), 217, 226, 269–270, 286–290
- P**
- PAGE. *See* Polyacrylamide gel electrophoresis  
Pall Corporation, 382–383  
Pam3Cys-Ser-(Lys)4 adjuvant, 115–116  
Paraffin tissue sections, preparing (protocol), 696–697  
Paraformaldehyde  
  fixing attached cells in (protocol), 705–706  
  fixing suspension cells with (protocol), 707  
Paraformaldehyde (4%) (recipe), 692, 695, 699, 706  
Paratopes, 354–355  
Partial proteolytic peptide maps, 760–761  
Particulate proteins, as immunogen form for immunizing animals, 117t, 118t  
*Pasteurella* infections, 114  
pBluescript, 412, 414  
PBS (recipe), 386, 394, 396, 400, 404  
pcDNA 3.1, 816f  
pComb3H, 422  
PCR. *See* Polymerase chain reaction  
pDEST 8, 818f  
pDEST 15, 817f  
pDEST 27, 817f  
PEG. *See* Polyethylene glycol  
Penicillin, addition to culture media, 304, 306t, 312, 325  
PEO (polyethylene oxide) iodoacetamide, for labeling antibodies by biotinylation, 438–439  
Pepsin, 438  
Peptide(s). *See also* Synthetic peptides  
  conjugation of peptides to thiol-reactive gel (protocol), 401–402  
  designing against highly homologous extracellular proteins, 53  
  sequence, choosing the appropriate, 52  
  size, 53  
  Peptide libraries, overlapping for determination of epitope location, 356–357  
  Peptide maps, partial proteolytic, 760–761  
  Peptide-specific antibodies, affinity purification of, 378  
Peritoneal macrophages  
  feeder plate preparation, 266  
  ridding cell lines of contaminating microorganisms with peritoneal macrophages, 327  
Permeabilized whole cells, antibody capture on immunofluorescence, 253–254  
  intracellular staining by flow cytometry/FACS, 249–250  
pET-SUMO, 816f  
pFABC, 412, 413f, 415–416  
pFastBac1, 816f  
pH  
  of antigen preparation, 54  
  cross-linking and, 62  
Phage  
  collection of particles, 420  
  panning for, 420

- Phage display, creation of recombinant antibodies using (protocol), 412–421
- discussion, 420
  - materials, 412–414
  - method, 414–420
    - amplification of gene III, 415
    - construction of cDNA library, 417–420, 419t
    - construction of Gene III-kappa c-region insert and ligation into pPDS, 415–416
    - construction of pLINK and pFABC, 416–417
    - construction of pPDS vector, 414
    - primer list, 419t
- Phagemids
- commercially available vectors, 412
  - in creation of recombinant antibodies using phage display (protocol), 412–421
- Phagocytosis, 33, 34, 35f
- Phosphatase inhibitors, in lysing yeast cells with glass beads protocol, 579–580
- Phosphate-based immunoblot wash buffer (PBST) (recipe), 508, 513, 518, 529
- Phosphate-buffered saline (PBS) (10×) (recipe), 513
- Phosphate buffered saline (PBS) (pH 7.4) (recipe), 650, 656, 660, 664, 668, 673
- Phosphatidyl serine, 749
- Phospho-specific antibodies, screening for, 214–215
- Photographing samples (protocol), 733
- Phycobilins, 448
- Phycocerythrin
- antibody conjugation to, 448, 452–454
  - properties of, 723t
- Pigs
- binding characteristics of Protein A, Protein G, and Protein L, 212t
  - IgG binding affinity for Proteins A, G, and L, 540t
- Plaque assay, 102–103
- Plasmablasts, 3, 3f, 32, 40, 40f
- Plasma cells, 3, 3f, 4, 32, 39, 45, 202
- Plasmid maps for bacterial expression, 813f–818f
- PlasmoTest Kit, 338–339, 339f
- pLenti/-TOPO expression vector, 104–105
- pLINK, 412, 413f, 415–416
- Polyacrylamide gel electrophoresis (PAGE)
- alternate buffer systems for discontinuous PAGE, 759t
  - protocols, 755–757
    - alkylation of proteins before running on a gel, 765
    - electroelution of protein antigens from polyacrylamide gel slices, 79–80
    - fragmenting a wet gel slice, 77
    - lyophilization of gel slice, 78
    - partial proteolytic peptide maps, 760–761
    - resolving proteins by, 490–496, 495t
      - gel formulations, 495t
      - materials, 491–492
      - method, 492–494
      - overview, 490
      - recipes, 495–496
      - separation range, 495t
      - troubleshooting, 494–495
    - side-strip method, 76
    - staining
      - Coomassie Brilliant Blue, 73
      - copper chloride, 75
      - sodium acetate, 74
    - two-dimensional isoelectric focusing/SDS-polyacrylamide gel electrophoresis, 762–764
  - in recombinant protein preparation process, 56
  - solutions for, 758t
- Polyacrylamide gels
- counting <sup>32</sup>P or <sup>125</sup>I from slices, 767
  - counting <sup>35</sup>S, <sup>14</sup>C, <sup>3</sup>H from slices, 767
  - drying, 773
  - fixing, 773
  - rehydrating dried, 774
  - transfer of proteins from gels to membranes, 497–508
    - overview, 497
    - semi-dry electrophoretic transfer (protocol), 499–502, 500f
    - staining the blot for total protein with Ponceau S (protocol), 507–508
    - wet electrophoretic transfer (protocol), 503–506
- Polyclonal antibodies
- animal species choice for producing, 110–111
  - for cell staining, 677–678, 677t
  - choosing versus monoclonal, 109, 110t, 203t, 354
  - by hyperimmunization, 126–127
  - immunoblotting, 472–473, 472t
  - immunochemical techniques using, 203t
  - immunological techniques, 47t
  - for immunoprecipitation, 537–538
  - monoclonal antibody versus, 47–48
  - multiple epitopes recognized by, 353–354
  - properties of, 109, 109t
- Polyethylene glycol (PEG)
- as fusing agent in hybridoma production, 205, 222
  - fusion (protocol), 274–278
    - day before fusion, 274–275
    - materials, 274
    - method, 274–276
    - postfusion cell culture, 276
    - recipes, 277–278
    - sample preparation, 275
    - spleen-myeloma fusion, 275–276
    - troubleshooting, 276–277
  - method for isolation of IgY from chicken eggs, 399–400
  - screening for good batches (protocol), 272–273
  - spacer, 436
- Polyethylene oxide (PEO) iodoacetamide, for labeling antibodies by biotinylation, 438–439
- Poly-histidine tags, 89–91
- Poly-L-lysine
- attaching suspension cells to slides using (protocols), 689
  - attaching yeast cells to slides using (protocol), 691–692
- Polymerase chain reaction (PCR)
- creation of recombinant antibodies using degenerate oligonucleotides (protocol), 407–409
  - creation of recombinant antibodies using phage display (protocol), 412–421
  - creation of recombinant antibodies using 5'-RACE (protocol), 410–411
  - MAP testing using, 60
  - modification of antibody function by mutagenesis (protocol), 422–423
  - rescue strategy for nonviable hybridomas (protocol), 424–427
  - single-cell PCR technology, 235
  - testing for mycoplasma contamination using PCR (protocol), 334–337, 335f
- Polysorbate 80, 384
- Polyvinyl chloride wells, antibody capture in enzyme-linked detection (indirect ELISA), 238–239
- enzyme-linked detection when immunogen is an immunoglobulin fusion protein (indirect ELISA to detect Ig fusion proteins), 240–241
- Polyvinylidene fluoride (PVDF) membranes
- blocking and incubation of immunoblots with antibodies, 509–518
  - immunoblots prepared with immunoprecipitated protein antigens (immunoprecipitation/western blotting), 515–518
  - immunoblots prepared with whole-cell lysates and purified proteins (straight western blotting), 510–514
- immunoblotting, 470
- staining immunoblot for total protein with Ponceau S (protocol), 507–508
- transfer of proteins from gels to membranes, 497–508
- overview, 497
  - semi-dry electrophoretic transfer (protocol), 499–502, 500f
  - staining the blot for total protein with Ponceau S (protocol), 507–508
  - wet electrophoretic transfer (protocol), 503–506
- Ponceau Red dye, 55
- Ponceau S, 81
- staining immunoblot for total protein with (protocol), 507–508
- Ponceau S solution (recipe), 508
- Pooled monoclonal antibodies for cell staining, 677t, 678
- Porcine thyroglobulin (PTG), coupling antigens to, 62
- [<sup>32</sup>P] orthophosphate
- metabolic labeling of antigens with [<sup>32</sup>P] orthophosphate (protocol), 558–562
- Posttranslational modification, 56, 57
- affinity purification of modification state-specific antibodies, 379
  - location of, 377
- PPD (purified protein derivative of tuberculin)
- coupling antigens to, 62
- PPDS, 412, 413f, 414–416
- PPO fluorography, 766, 775
- Precipitation of antigen, 54
- Precipitin line, 232, 292f
- Precision, ELISA, 640
- Primary response, 32
- Primers. *See* Polymerase chain reaction; *specific protocols*
- PROGEN Biotechnik, 409
- Programmed cell death (apoptosis) assessment (protocol), 749–750, 750f
- Proline exposure on protein surface, 52

- Propidium iodide, 749–754  
 Protean program, 51  
 Protease and phosphatase inhibitors (recipe), 570  
 Protease-free strains, 56  
 Protease inhibitors, 535, 536t, 794t  
   in lysing yeast cells with glass beads protocol, 579–580  
 Proteases, 794t  
   cell lysis and, 535  
   unmasking hidden epitopes with, 680  
 Protein A  
   in antibody capture assays, 210–211, 212t  
   avidity and, 27f, 28  
   binding characteristics of, 212t  
   chromatography, 375, 393–394  
   cross-linking antibodies to beads, 591–592  
   in cross-linking antibodies to beads using dimethyl pimelimidate protocol, 591, 592f, 593–596  
   in cross-linking antibodies to beads using disuccinimidyl subpimelimidate protocol, 591, 592f, 597–600  
   IgG binding affinity for, 539–540, 540t  
   in immune complex preparation for injection protocol, 70–71  
   immunoglobulin binding by, 375  
 Protein A/G agarose resin, 263  
 Protein-antibody conjugate formation, 448–454  
   labeling with Cy5-phycoerythrin (protocol), 452–454  
   overview, 448–449  
     alkaline phosphatase, 448  
     fluorescent proteins, 448–449  
     horseradish peroxidase, 448  
 Protein carriers, coupling antigens to, 62  
 Protein-free blocking buffers, 636  
 Protein G  
   in antibody capture assays, 210–211, 212t  
   chromatography, 375, 395–396  
   cross-linking antibodies to beads, 591–592  
   in cross-linking antibodies to beads using dimethyl pimelimidate protocol, 591, 592f, 593–596  
   IgG binding affinity for, 540, 540t  
   immunoglobulin binding by, 375  
 Protein L  
   in antibody capture assays, 211, 212t  
   in cross-linking antibodies to beads using dimethyl pimelimidate protocol, 591, 592f, 593–596  
   IgG binding affinity for, 540, 540t  
   immunoglobulin binding by, 375  
 Protein quantification, 789–793  
   bicinchoninic acid, 792  
   Bradford, 789  
   Bradford spot test, 790  
   Coomassie spot test, 790  
   Lowry, 792  
   NanoDrop, 793  
   UV detection, 791  
     protein solutions contaminated with nucleic acids, 791  
     pure protein solutions, 791  
 Protein sequence(s)  
   log-odds matrix for relationships between, 785t  
   motifs, 787t  
 Protein solutions, preparing for immunoblotting, 484–486  
 Protein-specific antibodies, affinity purification of, 378  
 Protein techniques, 777–797  
   amino acids, 780t  
   amino acid substitutions, 786t  
   ammonium sulfate saturation tables, 778t  
   chromogenic substrates  
     yielding water-insoluble products, 797t  
     yielding water-soluble products, 797t  
   codon usage, 783t–784t  
   concentration of protein samples by ultracentrifugation, 793  
   David's life chart II, 788t  
   dialysis tubing preparation, 795  
   genetic code, 781t  
   log-odds matrix for relationships between protein sequences, 785t  
   magnetic beads-immunoprecipitation, 793  
   mitochondrial genetic code, 782t  
   molecular weight standards, 779t  
   protease inhibitors, 794t  
   proteases, 794t  
   protein quantification, 789–793  
     bicinchoninic acid, 792  
     Bradford, 789  
     Bradford spot test, 790  
     Coomassie spot test, 790  
     Lowry, 792  
     NanoDrop, 793  
     UV detection, 791  
     protein solutions contaminated with nucleic acids, 791  
     pure protein solutions, 791  
   protein sequence motifs, 787t  
   TCA precipitation  
     filtration, 795  
     spotting, 796  
 Proteolytic peptide maps, partial, 760–761  
 ProtScale, 51  
 PTG (porcine thyroglobulin), coupling antigens to, 62  
 Pure antigens, 49t, 54–55  
 Purification. *See* Antibody purification  
 Purification tags. *See* Tag  
 Purified native proteins, 49t, 54–55
- ## Q
- Quantification limit, ELISA, 639, 641  
 Quantum dots, 455–456
- ## R
- Rabbits  
   administering anesthesia to (protocol), 139–141  
   age of immune maturation, 112  
   antigen dose for, 116–117, 117t  
   binding characteristics of Protein A, Protein G, and Protein L, 212t  
   bleed sample amount from, 110  
   boost injections in, 124  
   IgG binding affinity for Proteins A, G, and L, 539, 540t  
   injection routes for, 120, 121t  
   injection volume for, 121  
   intradermal injection in (protocol), 159–160, 160f  
   intramuscular injection in (protocol), 157–158, 158f  
   intravenous injection in (protocol), 161–162, 162f  
   sampling serum from marginal ear vein (protocol), 170–171, 170f  
   species choice for producing polyclonal antibodies, 110–111  
   standard immunization (protocol), 186–187  
   subcutaneous injection in (protocol), 150–151  
   test bleeds in, 128–129  
 Radiation  
   counting <sup>32</sup>P or <sup>125</sup>I from polyacrylamide gel slices, 767  
   counting <sup>35</sup>S, <sup>14</sup>C, <sup>3</sup>H from polyacrylamide gel slices, 767  
   detecting iodine-labeled reagents in cell staining protocols, 727–728  
   safety procedures, 822  
   waste disposal, 821, 822  
 Radiolabeling  
   antibodies, 461–463  
     iodination with immobilized iodogen (protocol), 462–463  
     overview, 461  
   autoradiography protocol, 83–84  
   SDS-PAGE gel and, 55  
 Range, ELISA, 642  
 RAS (Ribi Adjuvant System), 114t, 115, 144  
 Rats  
   administering anesthesia to (protocol), 136–138, 137f  
   age of immune maturation, 112  
   antigen dose for, 116, 118t  
   binding characteristics of Protein A, Protein G, and Protein L, 212t  
   bleed sample amount from, 110  
   cDNA immunization (protocol), 192–193, 193f  
   cell lines used for myeloma induction, 204t  
   decoy immunization for (protocol), 190  
   footpad or hock immunization (protocol), 168–169, 169f  
   IgG binding affinity for Proteins A, G, and L, 540t  
   immunizing with nitrocellulose bound antigen (protocol), 154–156, 155f  
   injection routes for, 120t  
   injection volume for, 121  
   intraperitoneal injection  
     with adjuvant in (protocol), 165, 165f  
     without adjuvant in (protocol), 166–167, 166f–167f  
   killing using carbon dioxide asphyxiation (protocol), 194–195  
   lymph node harvesting from (protocol), 198–199, 199f  
   repetitive immunization at multiple sites (RIMMS) (protocol), 188  
   serum sampling protocols  
     from retro-orbital sinus, 175–176, 176f  
     from submandibular vein, 177–178, 177f  
     from tail vein, 174  
   spleen harvesting from (protocol), 196–197, 197f  
   standard immunization (protocol), 184–185  
   subcutaneous injection  
     with adjuvant into (protocol), 152  
     without adjuvant into (protocol), 153  
   subtractive immunization (protocol), 189  
   test bleeds in, 128–129  
 RBCs. *See* Red blood cells  
 RCSB tools, 51  
 R&D Systems MycoProbe Kit, 334–337  
 Recipes  
   acidic stripping buffer, 528  
   AH selection medium, 351

Recipes (*Continued*)

- alkaline phosphatase buffer, 523, 720  
antigen dialysis buffer, 80  
antigen electrophoresis buffer, 80  
BCIP stock solution for AP, 523  
blocking buffer, 370  
blocking solutions, 513, 517, 529  
borate buffer (pH 8.0, 1×), 595  
borate buffer (pH 9.0, 1×), 595  
Bouin's fixative, 699  
buffer A for cross-linking antibodies to beads, 595, 599  
buffer A for dounce homogenization, 573  
buffer B for dounce homogenization, 573  
buffer C for dounce homogenization, 574  
buffer D for dounce homogenization, 574  
carbonate buffer, 650, 656, 660, 668, 673  
cDNA synthesis buffer, 411  
chasing medium, 556  
citrate binding buffer, 98  
citrate elution buffer, 99  
DAB substrate solution for HRP, 523  
developing solution (for AP), 239, 241  
developing solution (for Strep-AP), 259  
diaminobenzidine (DAB) solution, 257  
digitonin extraction buffer, 577  
dimethyl pimelidate (1×), 596  
disuccinimidyl glutarate (0.5 M), 627  
D-10 medium, 277  
DNA loading buffer (6×), 622  
Dulbecco's phosphate-buffered saline (pH 7.2, 1×), 599  
EBC lysis buffer, 622  
ECF buffer (1×), 284  
elution buffer, 623  
ethanolamine (1×), 596  
FACS buffer, 745  
formaldehyde solution (11%), 623  
fusion selection (HAT) medium, 268  
GST elution buffer, pH 8.0, 88  
GST lysis buffer, 88  
guanidine-chloride stripping buffer, 529  
HAT fusion medium, 278, 284  
HAT selection medium, 351  
His-fusion binding buffer, pH 7.4, 90  
His-fusion elution buffer, pH 7.4, 90  
His-fusion lysis buffer, pH 7.4, 91  
HMT selection medium, 351  
homemade chemiluminescent substrate solution for HRP: solution A, 523  
homemade chemiluminescent substrate solution for HRP: solution B, 524  
hydroxylamine buffer, 447, 451  
inclusion body lysis buffer, 96  
KLH buffer, 86  
label medium, 550, 556, 562  
Laemmli sample buffer (2×), 606, 612  
lysis buffer 1 (1×), 583, 587  
lysis buffer 2 (1×), 583  
lysis buffer 1 containing protease inhibitors, 583  
lysis buffer 1 for ChIP, 623  
lysis buffer 2 for ChIP, 623  
lysis buffer 3 for ChIP, 623  
MBP binding buffer, 93  
MBP elution buffer, 93  
MBP lysis buffer, 94  
NBT stock solution for AP, 524  
Nonidet P-40 lysis buffer, 567  
OPI supplement, 270, 285, 287, 290  
paraformaldehyde (4%), 692, 695, 699, 706  
PBS, 386, 394, 396, 400, 404  
phosphate-based immunoblot wash buffer (PBST), 508, 513, 518, 529  
phosphate-buffered saline (PBS) (10×), 513  
phosphate buffered saline (PBS) (pH 7.4), 650, 656, 660, 664, 668, 673  
Ponceau S solution, 508  
protease and phosphatase inhibitors, 570  
RIPA buffer, 567, 623  
Sarkosyl buffer, pH 7.4, 96  
saturated ammonium sulfate, 386  
SDS-PAGE running buffer (1×), 495  
SDS-PAGE sample buffer (1×), 482  
SDS-PAGE sample buffer (2×), 483, 485, 489  
SDS-PAGE sample buffer (3×), 485  
SDS-PAGE sample buffer (6×), 486  
semi-dry transfer buffer (1×), 502  
semi-dry transfer buffer stock solution (25×, without methanol), 502  
separating gel buffer (4×), 496  
sodium acetate, 388  
solution A for cross-linking antibodies to beads, 596  
solution B for cross-linking antibodies to beads, 596  
sorbitol buffer, 692  
stacking gel buffer (4×), 496  
starvation medium, 551, 556, 562  
stock buffer (4×), 577  
stock buffer (10×), 577  
stripping buffer with SDS, 530  
TBS (0.1 M), 386, 394, 396, 398, 404  
tissue lysis buffer, 570  
transfer buffer 1, 505  
transfer buffer 2, 506  
Tris-based immunoblot wash buffer (TBST), 508, 514, 518, 530  
Tris buffered saline (TBS), 650, 656, 660, 664, 668, 673  
Tris-buffered saline (TBS) (10×), 514, 518  
Tris dialysis buffer, 454  
Triton X-100 extraction buffer, 577  
Trypan Blue stain (0.4%), 574, 578, 583  
trypsin solution, 257  
Tween 40/deoxycholate extraction buffer, 578  
wash buffer, 606, 612  
water-saturated isobutyl alcohol, 496
- Recombinant antibodies**  
creation using degenerate oligonucleotides (protocol), 407–409  
discussion, 408–409  
materials, 407–408  
method, 408  
creation using phage display (protocol), 412–421  
discussion, 420  
materials, 412–414  
method, 414–420  
amplification of gene III, 415  
construction of cDNA library, 417–420, 419t  
construction of Gene III-kappa c-region insert and ligation into pPDS, 415–416  
construction of pLINK and pFABC, 416–417  
construction of pPDS vector, 414  
primer list, 419t  
creation using 5'-RACE (protocol), 410–411  
materials, 410  
method, 410–411  
recipe, 411  
modification of antibody function by mutagenesis (protocol), 422–423  
materials, 422  
method, 423  
rescue strategy for nonviable hybridomas (protocol), 424–427  
materials, 424–425  
method, 425–427
- Recombinant murine IL-6**, 217
- Recombinant proteins**  
expression system selection, 55, 57t, 58t  
as immunogens, 49t, 55–59, 119  
advantages and disadvantages of use, 49t  
from bacterial overexpression vectors, 55–56, 56t  
from baculovirus overexpression vectors, 56  
choosing between proteins and peptides, 57–59, 57t, 58t  
from mammalian overexpression vectors, 56–57
- Recombination. See also DNA, rearrangements**  
allelic exclusion and, 17–18  
antibody diversity and, 17  
class and subclass switching, 18f, 19, 39  
T-cell receptor diversity and, 35
- Recovering cells from liquid nitrogen storage**, 323–324
- Red blood cells, coupling antigens to**, 63, 72
- Regulatory T cells (Tregs)**, 6
- Rehydrating dried polyacrylamide gels**, 774
- ReliaBLOT**, 509
- Repetitive immunization at multiple sites (RIMMS)**, 124, 125f, 125t, 188
- Reporter cells, testing for mycoplasma contamination using (protocol)**, 338–339, 339f
- Reprobing membranes after immunoblotting**, 526–530  
overview, 526  
stripping the blot for reprobing, 527–530
- Rescue strategy for nonviable hybridomas (protocol)**, 424–427  
materials, 424–425  
method, 425–427
- Resonance wave grafting**, 360
- Reticuloendothelial system**, 33
- Retro-orbital sinus, sampling mouse and rat serum from (protocol)**, 175–176, 176f
- Reverse dot blot**  
antigen capture assay, 214  
protocol, 261–262
- Reversed-phase chromatography, for cleanup and purification of antibody conjugates**, 465
- Rhodamine**  
detecting fluorochrome-labeled reagents in stained cells (protocol), 722–724  
properties of, 723t
- Ribi Adjuvant System (RAS)**, 114t, 115, 144
- RIMMS (repetitive immunization at multiple sites)**, 124, 125f, 125t, 188
- RIPA buffer (recipe)**, 567, 623
- RLM-RACE**, 410
- RNA blotting**, 470
- RNA interference (RNAi)**, 474
- Roller bottles, growing hybridomas in**, 314
- Routes of injection. See Injection routes**
- RPMI 1640 medium**, 304, 305t–306t

## S

- Saccharomyces cerevisiae*. See Yeast
- SAF-1 adjuvant, 114
- Safety, 819–824
- biological safety procedures, 822–823
  - general cautions, 819–821
  - institutional safety office, 819
  - material safety data sheets (MSDSs), 819
  - properties of common hazardous chemicals, 823–824
  - radioactive safety procedures, 822
  - waste disposal, 821
- Sandwich ELISA
- antibody capture, 211f
  - antigen capture assay, 214
  - antigen capture in 96-well plates (protocol), 258–260
  - checkerboard titration of antigen and antibody by serial dilution, 654t
  - immunometric antibody, 651–657, 652f, 654t, 655f–656f
  - immunometric double-antibody, 658–660, 658f
  - isotype determination of rodent-derived monoclonal antibodies using sandwich ELISA (protocol), 366–370
  - optimizing pairwise antibody concentrations, 654–655
- Saphenous vein, sampling mouse and rat serum from (protocol), 179–180, 180f
- Sarkosyl buffer, pH 7.4 (recipe), 96
- Sarkosyl preparation of antigens from bacterial inclusion bodies (protocol), 95–96
- SATA. See *N*-succinimidyl *S*-acetylthioacetate
- Saturated ammonium sulfate (recipe), 386
- [<sup>35</sup>S] cysteine
- metabolic labeling of antigens with [<sup>35</sup>S] methionine (protocol), 546–551
- SDS. See Sodium dodecyl sulfate
- SDS-PAGE. See Electrophoresis; Polyacrylamide gel electrophoresis
- SDS-PAGE running buffer (1×) (recipe), 495
- SDS-PAGE sample buffer
- for preparing protein solutions for immunoblotting (protocol), 484–486
  - for preparing whole-cell lysates for immunoblotting (protocol), 480–483
- SDS-PAGE sample buffer (1×) (recipe), 482
- SDS-PAGE sample buffer (2×) (recipe), 483, 485, 489
- SDS-PAGE sample buffer (3×) (recipe), 485
- SDS-PAGE sample buffer (6×) (recipe), 486
- SDS-polyacrylamide gel electrophoresis (SDS-PAGE). See also Electrophoresis; Polyacrylamide gel electrophoresis
- alkylation of proteins before running on a gel, 765
  - alternate buffer systems for discontinuous PAGE, 759t
  - gel fragment processing, 55
  - native protein isolation by, 54–55
  - partial proteolytic peptide maps, 760–761 protocol, 755–757
  - solutions for, 758t
  - staining, 55
  - two-dimensional isoelectric focusing/SDS-polyacrylamide gel electrophoresis, 762–764
- SEAP (secreted embryonic alkaline phosphatase), 338, 339f
- Secondary antibodies, reporter-labeled, 636–637, 637t
- Secondary lymphoid organs, 3–4
- Secondary response, 32, 33
- Secondary structure, predicting, 51
- Secreted embryonic alkaline phosphatase (SEAP), 338, 339f
- Self-tolerance, failure of, 46
- Semi-dry electrophoretic transfer (protocol), 499–502, 500f
- materials, 499–500
  - method, 500–501
  - recipes, 501–502
  - schematic for, 500f
  - troubleshooting, 501
- Semi-dry transfer buffer (1×) (recipe), 502
- Semi-dry transfer buffer stock solution (25×, without methanol) (recipe), 502
- Sendai virus, 221, 279–280
- Sensitivity, ELISA, 641
- Separating gel buffer (4×) (recipe), 496
- Sephadex resins, 464, 464t
- Sequence homologies, checking for, 51
- Sequence motifs, protein, 787t
- Serum
- for ELISA blocking, 636
  - preparation, 129
  - protocol, 181
- Serum-free medium, 304, 306–307, 307t
- Serum sampling
- methods of blood sampling, 128t
  - protocols, 170–181
  - sampling mouse and rat serum from retro-orbital sinus, 175–176, 176f
  - sampling mouse and rat serum from saphenous vein, 179–180, 180f
  - sampling mouse and rat serum from submandibular vein, 177–178, 177f
  - sampling mouse serum from tail vein, 172–173, 173f
  - sampling rabbit serum from marginal ear vein, 170–171, 170f
  - sampling rat serum from tail vein, 174
  - test bleeds, 127–129
- Sheep
- binding characteristics of Protein A, Protein G, and Protein L, 212t
  - IgG binding affinity for Proteins A, G, and L, 540t
- Shizosaccharomyces pombe*. See Yeast
- Side-strip method (protocol), 76
- Signal amplification scale, 478
- Silver staining of gels (protocols)
- ammoniacal silver staining, 770
  - neutral silver staining, 771
- Simple multiplexed antibody-binding assay (protocol), 742–745, 744f, 744t
- Single-cell cloning
- by growth in soft agar (protocol), 288–290
  - by limiting dilution (protocol), 286–287
  - ridding cells of mycoplasma contamination using antibiotics and single-cell cloning (protocol), 340–341
- 6x His, 55, 56t
- Size-exclusion chromatography
- for cleanup and purification of antibody conjugates, 464, 464t, 467–468
  - desalting or buffer exchange using (protocol), 467–468
- Slide-A-Lyzer MINI Dialysis Unit, 572
- SMARTer RACE, 410
- SMCC (succinimidyl 4-(*N*-maleimidomethyl)cyclohexane-1-carboxylate), in antibody conjugation to horseradish peroxidase protocol, 450–451
- [<sup>35</sup>S] methionine
- metabolic labeling of antigens with [<sup>35</sup>S] methionine (protocol), 546–551
  - pulse-chase labeling of antigens with [<sup>35</sup>S] methionine (protocol), 552–557
- Sodium acetate, 55
- staining protocol, 74
- Sodium acetate (recipe), 388
- Sodium azide, 383
- Sodium deoxycholate (DOC), 535
- in differential detergent lysis of cellular fractions protocol, 575–576
- Sodium dinitrobenzene sulfonic acid (DNBS), 66
- Sodium dodecyl sulfate (SDS)
- for cell lysis, 535
  - in denaturing cell lysis (protocol), 588–590
  - for denaturing proteins, 474–475
  - screening for bacterial expression by SDS lysis, 810
- Sodium metaperiodate, 432
- Sodium pentobarbital for anesthesia, 112
- Sodium sulfate method, for isolation of IgY from chicken eggs, 397–398
- Soft agar
- hybridoma plating strategies, 224, 224f
  - single-cell cloning by growth in (protocol), 288–290
- Soluble proteins, as immunogen form
- for immunizing animals, 117t, 118, 118t
- Solution A for cross-linking antibodies to beads (recipe), 596
- Solution B for cross-linking antibodies to beads (recipe), 596
- Solvents
- fixing attached cells in organic (protocol), 703–704
  - safe handling of, 820, 823
- Somatic hypermutation, 17, 18
- Somatic mutation, 33, 39
- Sorbitol buffer (recipe), 692
- SPDP (*N*-succinimidyl-3-(2-pyridyldithio)-propionate), 433
- Specificity
- antibody, 23, 353–354
  - ELISA, 642
- Spleen
- cell collection from, 275
  - harvesting, 196–197, 197f, 220f
  - injection into, 123
- Splenocytes
- feeder cell culture preparation (protocol), 269–270
  - preparing for fusions, 219–220, 219f–221f
  - spleen-myeloma fusion protocol, 275–276
- SPR (surface plasmon resonance), for measurement of antibody affinity, 360
- Stacking gel buffer (4×) (recipe), 496
- Staining. See also Cell staining
- cell-permanent dye, 742–743
  - immunoblot, 497, 507–508
  - protocols
    - Coomassie Brilliant Blue, 73
    - maximal sensitivity, 769

- Staining. *See also* Cell staining (*Continued*)  
 quick method, 768  
 standard method, 768  
 copper chloride, 75, 772  
 immunoblot for total protein with Ponceau S, 507–508  
 silver staining of gels  
 ammoniacal silver staining, 770  
 neutral silver staining, 771  
 sodium acetate, 74  
 testing for mycoplasma contamination by Hoechst dye 33258 staining, 332–333, 333f  
 SDS-PAGE gels, 55  
 for viability check with Trypan Blue, 320  
 Standards, molecular weight, 779t  
 Starvation medium (recipe), 551, 556, 562  
 Stock buffer (4×) (recipe), 577  
 Stock buffer (10×) (recipe), 577  
 Stock solutions, preparation of, 801t–802t  
 Storage  
 of antibody, 383–384  
 of antibody conjugates, 466  
 of hybridomas, 309  
 in liquid nitrogen  
 freezing cells for, 321–322  
 recovering cells from, 323–324  
 Streptavidin, 632, 681  
 enzyme-labeled, 516  
 fluorochrome-labeled, 516–517  
 Streptavidin-alkaline phosphatase, 258–259  
 StrepTactin, 55, 56t  
 Streptomycin, addition to culture media, 304, 306t, 312, 325  
 Stripping an immunoblot for reprobing, 527–530  
 Stripping buffer with SDS (recipe), 530  
 Subcutaneous injection, 120–121  
 with adjuvant into mice and rats (protocol), 152  
 in rabbits (protocol), 150–151  
 without adjuvant into mice and rats (protocol), 153  
 Submandibular vein, sampling mouse and rat serum from (protocol), 177–178, 177f  
 Substrates, ELISA, 637–639  
 chemifluorescent, 638–639  
 chemiluminescent, 638  
 chromogenic (colorimetric), 637–638  
 Subtractive immunization, 60  
 for mice, rats, and hamsters (protocol), 189  
 Succinimidyl 4-(*N*-maleimidomethyl) cyclohexane-1-carboxylate (SMCC), in antibody conjugation to horseradish peroxidase protocol, 450–451  
*N*-succinimidyl-3-(2-pyridyldithio)-propionate (SPDP), 433  
*N*-succinimidyl *S*-acetylthioacetate (SATA), 433  
 in antibody conjugation to horseradish peroxidase protocol, 450–451  
 labeling antibodies using a maleimido dye (protocol), 446–447  
 Succinimidyl 4-formylnebozate, 432  
 Sulfhydryls  
 biotinylating antibodies using biotin polyethylene oxide (PEO) iodoacetamide (protocol), 438–439  
 cross-linking sites for labeling antibody, 432t, 433, 433t  
 Supernatant collection strategies for screening, 224–225  
 Suppressor B cells, 6  
 Surface plasmon resonance (SPR), for measurement of antibody affinity, 360  
 Surface staining  
 by flow cytometry/FACS, 246–248  
 by immunofluorescence, 251–252  
 Surfactants, 113  
 Suspension cells  
 attaching cells to slides  
 using cytocentrifuge, 688  
 using poly-L-lysine, 689  
 fixing with paraformaldehyde, 707  
 preparing for staining, 679  
 Synthetic peptides as immunogens, 49t, 50–54, 119  
 advantages and disadvantages of use, 49t, 51  
 carrier selection, 54  
 choosing over recombinant protein, 57–59  
 coupling strategy, 53–54  
 designing the peptide, 51–52  
 peptide design against highly homologous extracellular proteins, 53  
 peptide sequence choice, 52  
 size of peptide, 53  
 T  
 Tag(s), 55, 56t, 58  
 antigenicity of, 58  
 epitope, 539  
 protocols  
 GST-fusion protein preparation from bacteria, 87–88  
 His-fusion protein preparation from bacteria, 89–91  
 MBP-fusion protein preparation from bacteria, 92–94  
 surface for transfection of cells, 59  
 tandem affinity purification (TAP) tags, 539  
 Tail vein  
 sampling mouse serum from (protocol), 172–173, 173f  
 sampling rat serum from (protocol), 174  
 Tandem affinity purification (TAP) tags, 539  
 Tandem immunoaffinity purification using anti-FLAG and anti-HA antibodies (protocol), 607–612  
 discussion, 611  
 materials, 607–608  
 method: anti-FLAG purification, 607–608  
 method: anti-HA purification, 609–610  
 recipes, 612  
 troubleshooting, 610t–611t  
 TAP (tandem affinity purification) tags, 539  
 TBS (0.1 M) (recipe), 386, 394, 396, 398, 404  
 TCA. *See* Trichloroacetic acid (TCA) precipitation  
 T-cell-B-cell synapse, 36–37  
 T-cell-dependent antigens, 33  
 T-cell-independent antigens, 34  
 T-cell receptor (TCR)  
 diversity of, 35  
 MHC peptide binding, 36  
 structure of, 35  
 T follicular helper cell activation, 36, 37f  
 T-cell receptor–MHC-class II protein-binding sites, coupling antigens with, 62–63  
 T cells  
 helper, 35, 36  
 memory, 33  
 regulatory (Tregs), 6  
 T-cell tolerance, 38, 39, 46, 62  
 TCR. *See* T-cell receptor  
 TDM (trehalose dimycolate), 115  
 TEMED (tetramethylethylenediamine), 491–493  
 Terminal deoxynucleotide transferase (TdT), 410–411  
 1,4,7,10-tetraazacyclododecane-tetraacetic acid (DOTA), 455, 457  
 Tetramethylbenzidine (TMB), 637–638  
 Tetramethylethylenediamine (TEMED), 491–493  
 Texas Red, 722–724, 723t  
 T-flasks, growing hybridomas in, 314  
 Thiol-reactive gel, conjugation of peptides to (protocol), 401–402  
 Tissue  
 antibody capture on tissue sections (immunohistochemistry), 255–257  
 detergent lysis of animal tissues (protocol), 568–570  
 harvesting protocols, 194–199  
 killing mice, rats, and hamsters using carbon dioxide asphyxiation, 194–195  
 lymph node harvesting from mice, rats, and hamsters, 198–199, 199f  
 spleen harvesting from mice, rats, and hamsters, 196–197, 197f  
 lysates as immunogen source, 49t, 59–60  
 lysis of, 536–537, 568–570  
 mounting samples  
 in DPX, 730  
 in Gelvatol or Mowiol, 731  
 preparing, overview of, 679–680  
 preparing cell smears from tissue samples or cell cultures (protocol), 700  
 preparing frozen tissue sections (protocol), 693–695  
 preparing paraffin tissue sections (protocol), 696–697  
 preparing sections for staining, 679–680  
 Tissue culture. *See also* Cell cultures  
 cell lysis, 535–536  
 collecting tissue culture supernatants (protocol), 346  
 detergent lysis of tissue culture cells (protocol), 565–567  
 storing tissue culture supernatants and ascites (protocol), 347–348  
 Tissue culture dishes, growing adherent cells on (protocol), 687  
 Tissue lysis buffer (recipe), 570  
 TiterMax adjuvant, 114t, 115, 145  
 TMB (tetramethylbenzidine), 637–638  
 Tolerance, 6, 46  
 Toll-like receptors (TLRs)  
 described, 2  
 Magic Mouse adjuvant and, 115, 146  
 simulation of B cells, 33, 34  
 Toll-like receptor 2 (TLR2), for mycoplasma detection, 338–339, 339f  
 Tonsil tissue, stained, 714f  
 Toxic compounds, 824  
 Toxin, pertussis, 113  
 Transfectants, use for immunization, 59–60  
 Transfected dendritic cell immunizations (protocol), 104–106  
 Transfer buffer 1 (recipe), 505  
 Transfer buffer 2 (recipe), 506

- Transfer of proteins from gels to membranes, 497–508  
 overview, 497  
 semi-dry electrophoretic transfer (protocol), 499–502, 500f  
 staining the blot for total protein with Ponceau S (protocol), 507–508  
 wet electrophoretic transfer (protocol), 503–506
- Trehalose dimycolate (TDM), 115
- 1,4,7-triazacyclononane-*N,N',N''*-triacetic acid (NOTA), 455
- Trichloroacetic acid (TCA) precipitation  
 filtration, 795  
 spotting, 796
- Tris-based immunoblot wash buffer (TBST) (recipe), 508, 514, 518, 530
- Tris-buffered saline (TBS) (10×) (recipe), 514, 518
- Tris buffered saline (TBS) (recipe), 650, 656, 660, 664, 668, 673
- Tris dialysis buffer (recipe), 454
- Tris/glycine SDS-polyacrylamide gel electrophoresis  
 protocol, 755–757  
 solutions for, 758t
- Tris/glycine SDS-polyacrylamide gel electrophoresis, resolving proteins by (protocol), 490–496, 495t
- Triton X-100, 535  
 in differential detergent lysis of cellular fractions protocol, 575–576  
 in lysing yeast cells with glass beads using lysis buffer 2 without detergents (protocol), 582
- Triton X-100 extraction buffer (recipe), 577
- Trp fusion vectors, 814f
- Trypan Blue, 320, 580
- Trypan Blue stain (0.4%) (recipe), 574, 578, 583
- Trypsin, affinity of, 24
- Trypsin solution (recipe), 257
- TSA (tyramide signal amplification), 713
- T7 vectors, 813f
- Tween 20, as blocking solution, 509
- Tween 40, in differential detergent lysis of cellular fractions protocol, 575–576
- Tween 40/deoxycholate extraction buffer (recipe), 578
- Two-dimensional isoelectric focusing/  
 SDS-polyacrylamide gel electrophoresis, 762–764
- Tylosin, addition to culture medium, 340–341
- Tyramide signal amplification (TSA), 713
- Tyrosine, arsanilic acid coupling to, 67
- ## U
- Ultracentrifugation, concentration of protein samples by, 793
- Ultrasonicators, 820–821
- UV detection for protein quantification, 791  
 protein solutions contaminated with nucleic acids, 791  
 pure protein solutions, 791
- ## V
- Vaccination. *See also* Antibody responses; Immunization  
 adjuvants, 33–34  
 tolerance induction, 38
- VCS-M13 helper phage, 412, 420
- VDJ joining, heavy-chain, 16, 16f
- VECTASTAIN Kit, 255–256
- Velocimouse, 236
- VERSENE, 249
- Viability checks (protocol), 320
- Virus titer determination, 102–103
- V-J joining  
 $\kappa$  gene, 15, 15f  
 lambda, 15, 16f
- V8 protease, 760–761
- ## W
- Wash buffer (recipe), 606, 612
- Waste, disposal of, 821, 822
- Water-saturated isobutyl alcohol (recipe), 496
- Western blot assay for hybridoma screening, high-throughput (protocol), 244–245
- Western blotting. *See also* Immunoblotting  
 blocking and incubation with antibodies:  
 immunoblots prepared with immunoprecipitated protein antigens (protocol), 515–518  
 blocking and incubation with antibodies:  
 immunoblots prepared with whole-cell lysates and purified proteins (protocol), 510–514
- Wet electrophoretic transfer (protocol), 503–506  
 materials, 503  
 method, 503–505  
 recipes, 505–506  
 schematic of, 504f  
 troubleshooting, 505
- ## Whole cells
- antibody capture on whole cells (protocols)  
 cell-surface binding (surface staining by flow cytometry/FACS), 246–248  
 cell-surface binding (surface staining by immunofluorescence), 251–252  
 preparing lysates for immunoblotting (protocol), 480–483
- ## X
- X-gal, detecting  $\beta$ -galactosidase-labeled cells using (protocol), 721
- X-ray crystallography, of epitopes, 355
- Xylene  
 mounting cell or tissue samples in DPX (protocol), 730
- ## Y
- Yeast  
 attaching cells to slides using poly-L-lysine (protocol), 691–692  
 contamination of cell cultures, 230f, 309–310  
 overview, 309–310  
 ridding cell lines of by antibiotics (protocol), 325–326  
 ridding cell lines of by passage through mice (protocol), 328–329  
 ridding cell lines of with peritoneal macrophages (protocol), 327
- lysing cells, 537  
 with glass beads (protocol), 579–581  
 using lysis buffer 2 without detergents (protocol), 582–584  
 protocol, 708  
 using a coffee grinder (protocol), 585–587
- protein expression system, 58t  
 staining cells, 679

This is a free sample of content from *Antibodies: A Laboratory Manual, Second Edition*.  
[Click here for more information or to buy the book.](#)